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Screening a library of 5,292 hydrazone/hydrazine compounds for inhibition of HIV reverse 
transcriptase-associated ribonuclease H (RNH) activity identified fluoren-9-yildene hydrazines 
as highly active inhibitors.  The 33 fluoren-9-yildene hydrazines in this library were expanded to 
118 compounds, 65 (55%) of which showed validated inhibition of RT RNH activity (IC50 
values < 10 M).  These inhibitors were mainly monofunctional for RNH activity, since only 25 
(21%) also inhibited RT RNA-dependent DNA polymerase activity.  The two most potent RNH 
inhibitors (RNHIs) were compounds 15 and 25, which inhibited wild type RT-RNH activity with 
IC50 values of 0.34 ± 0.07 M and 0.4 ± 0.03 M, respectively.  Similar inhibition was noted 
with two clinically relevant NNRTI resistant mutants, Y181C and K103N/L100V.  Biochemical 
studies showed that these compounds preferentially inhibited non-directed and DNA 3'-end 
directed RNH cleavages.  These compounds also inhibited the activity of the p15-EC RT RNH 
domain fragment with IC50 values of 0.43 ± 0.04 M and 0.032 ± 0.004 M, respectively.  
Furthermore, both compounds had antiviral activity against HIV-1 with EC50 values of 10 ± 3 
M and 1.4 ± 0.6 M for compounds 15 and 25, respectively.  Order of addition experiments 
showed that potent inhibition required pre-incubation of the enzyme with the inhibitor; inhibitory 
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potency substantially decreased if the RNA/DNA substrate was present prior to inhibitor 
addition.  Furthermore, inhibition was competitive with respect to the RNA/DNA substrate, 
suggesting an active site binding mode.  1H-15N HSQC protein NMR studies with the p15-EC RT 
RNH domain fragment further suggested that the inhibitor binds to the RNH active site.  
Molecular docking studies with compound 25 were consistent with an active site binding mode 
in which the hydrazine functionality hydrogen bonds with essential catalytic metal coordinating 
residues E52 (RT: 478) and D72 (RT: 498).  A sulfonamido-phenyl ring substituent on 
compound 25 makes edge on-π interactions with H127 (RT: 539), another residue essential for 
RNH catalysis.  We therefore propose that the fluoren-9-ylidene hydrazine RNHIs act by 
preventing access of RNH essential catalytic residues to the RNA/DNA substrate.  
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in infected cells; and third, killing of infected CD4 T-cells by CD8 cytotoxic lymphocytes that 
recognize infected cells.  When CD4 T-cell numbers decline below a critical level, cell-mediated 
immunity is lost, and the body becomes progressively more susceptible to opportunistic 
infections.  HIV has an (+) RNA genome (Figure 1), that consists of nine genes (gag, pol, env, 
tat, rev, nef, vif, vpr and vpu) encoding 19 proteins.  The six genes tat, rev, nef, vif, vpr, and vpu 
(or vpx in the case of HIV-2), are regulatory genes for proteins that control the ability of HIV to 
infect cells, produce new copies of virus (replicate), or cause disease.  The gag gene encodes the 
viral structural proteins, while the env gene encodes for the envelope proteins essential for 
cellular attachment and entry.  Lastly the pol gene, encodes for essential enzymes, including 
reverse transcription (RT), integrase (IN) and protease (PR) that are responsible for viral 
transcription, integration and cleavage, respectively.   
 
 
 
 
1.2 HIV-1 Reverse Transcriptase 
 
 
 
 
1.2.1 Significance of HIV-1 RT Polymerase and RNH Activities in Viral Replication 
 
 
HIV-1 reverse transcriptase is an essential multifunctional enzyme of HIV-1 replication.  RT has 
both RNA and DNA dependent polymerase activity, along with an essential ribonuclease H 
(RNH) activity.  All three functions associated with RT are equivalently indispensable for viral 
replication; since the RT enzyme is required to reverse transcribe the viral (+) RNA genome into 
a double stranded DNA (dsDNA) genome.  Upon absorption of the virus by the host cell and 
release of two (+) RNA viral genomes into the host cytoplasm, the activities of HIV-1 RT are 
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initiated from a host tRNAlys3 that is annealed to the primer binding site (PBS) of the (+) RNA 
genome and catalyzed by the RNA dependent polymerase (RDDP) activity of RT.  The RDDP 
activity of RT transcribes the (+) RNA genome to synthesize the complementary (-) DNA strand, 
which undergoes strand transfer of the terminal repeat regions to the same or another co-
packaged viral (+) RNA strand.  This strand transfer process requires RT-RNH activity to 
degrade the (+) RNA component complementary to the newly synthesized (-) strong stop DNA.  
RT DNA dependent DNA polymerase (DDDP) activity then forms the complimentary (+) DNA 
strand to complete synthesis of the viral duplex DNA (Figure 2).   
 
  
 
 
Figure 2. HIV-1 Reverse Transcription. Figure acquired from Sarafianos, S.G. et al. 2009 (76). 
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1.2.2 Structure of HIV-1 RT  
 
 
HIV-1 RT is a heterodimer composed of both a 51 kDa (p51) and 66 kDa (p66) subunits that 
have identical primary sequence and secondary components, but differ in tertiary orientation 
(Figure 3).  The p51 subunit is formed by proteolytic removal of the 15 kDa RNH domain during 
viral maturation.  The cleavage occurs between residues F440/Y441 (13, 23, 46, 96), thereby 
creating the catalytically active p51/p66 heterodimer of RT (73) that is optimal for viral 
replication (1).  The intact p66 subunit contains both the polymerase and RNH active sites, 
spatially separated by about 40 Å , corresponding to a distance of approximately 17 nucleotides 
on a DNA/DNA substrate (48, 49) or 18 nucleotides apart with an RNA/DNA substrate (75).  
The polymerase domain of the p66 subunit of RT can be broken down into four subdomains 
containing the fingers (residues 1-85 and 118-155), palm (residues 86-117 and 156-236), thumb 
(residues 237-318) and connection (residues 319-426) subdomains (76), with a tertiary structure 
similar to a right hand.  The polymerase active site is located within the palm subdomain 
between the thumb and finger subdomains, with catalytic residues D110, D185 and D186 
(Figure 3).  The p51 subunit, without any catalytically active sites, contains identical subdomains 
as seen with the p66's polymerase domain, where the thumb subdomain of p51 is oriented in 
such a manner that it makes direct contact with the base of p66's RNH domain, near the RNH 
active site.  The connection domain of the p66 subunit is responsible for linking both the RNH 
and polymerase domains and has significant contacts with the substrate's DNA strand (75).  
Furthermore, mutational studies has indicated residue H361 of the connection subdomain to be 
highly significant for in vitro RNH activity and during in vivo experiments causes a depletion in 
viral titers, indicating the significance of the connection subdomain for RNH activity (52) .  Even 
though the p51 subunit is catalytically inactive, it does act as a structural scaffold for the p66 
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subunit during both polymerization and RNH catalysis (2), while maintaining significant contact 
with the substrate.  The significance of the p51 subunit is further supported by the fact that the 
isolated RNH domain is catalytically inactive.  The activity of the isolated domain can be 
restored by introducing the p51 subunit or adding various N-terminal fusions to the RNH domain 
that take on the substrate interacting roles of the p51 subunit, including an extended C-helix loop 
found with E. coli RNH (p15-EC) (22, 47, 54, 85, 86, 87, 88, 89). 
 
 
 
 
 
 
Figure 3.  Structure of HIV-1 RT.  The p66 subunit is denoted in teal with the c-terminal RNH  
domain denoted in pink, while green dotted spheres represent both the polymerase 
and RNH active site residues.  Light gray indicates the p51 subunit. HIV-1 RT 
structure was obtained from PDB file 2I5J (43) and rendered using Pymol software 
(DeLano Scientific LLC, San Carlos, California). 
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1.3 HIV-1 REVERSE TRANSCRIPTASE RIBONUCLEASE H DOMAIN 
 
 
 
 
1.3.1 Structure of HIV-1 RT-RNH Domain 
 
 
 
 
 
Figure 4. Structure of HIV-1 RT-RNH Domain.  The RNH domain is depicted in violet and  
green spheres represent the active site residues D443, E478, D98 and D549.  The 
HIV-1 RT-RNH domain structure is rendered using pymol software (DeLano 
Scientific LLC, San Carlos, California) with the PBD file 2I5J (43).  
   
 
 
Numerous X-ray crystal structures of RT-RNH have been solved either as the isolated domain or 
as the intact RT molecule (16, 48, 58).  Co-crystal structures have also been determined with the 
RT and its DNA/DNA (4, 49) or RNA/DNA (75) substrates.  The RNH domain (Figure 4) 
contains p66 subunit C-terminal residues 427-560 and has a fold similar to E. coli RNH.  HIV-1 
RNH is an α-β protein, folded into a five-stranded mixed β-sheet with four flanking asymmetric 
α-helices.  The RNH active site resides within a defined pocket containing four conserved 
catalytic acidic residues (D443, E478, D498 and D549) coordinate to two metal cations (16).  
Co-crystal structure of HIV-1 RT with an RNA/DNA hybrid substrate demonstrates that the 
RNH domain binds the minor grove of the nucleic acid and has direct interaction with both the 
RNA and DNA strands.  A region adjacent to the RNH active site, the RNH primer grip is 
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responsible for interacting with the DNA primer strand at the complementary base paired RNA 
nucleotides, at positions -4 and -9, relative to the scissile phosphate.  RNH protein substrate 
contacts are made with residues K395 and E396 (p51 subunit), G359, A360, and H361 (p66 
subunit), along with residues T473, N474, Q475, K476, Y501 and I505 (RNH domain of p66) 
(75).  The RNH primer grip is essential for proper binding and positioning of the substrate, 
extending from both the polymerase and RNH active sites and has been shown to have an 
influence on both DNA polymerization and RNH catalysis through point mutational studies (3, 
51, 52, 66, 72, 104).  RNH primer grip residues Y501 and Q475 are highly significant for RNH 
activity.  Residue Y501 has direct contact with the DNA phosphate backbone (66, 75) and has a 
substantial influence on the efficiency and specificity of RNH cleavages, where any substitutions 
at this position either completely abrogates RNH activity or substantially reduces it (3, 66, 72).  
Residue Q475 has direct contact with the DNA deoxyribose rings (75) and mutational studies 
have also shown this residue to be significant for RNH cleavage specificity (72). 
 
 
 
 
1.3.2 Hydrolysis by RT-RNH 
 
 
HIV-1 RT-RNH is an endonuclease that hydrolyzes the RNA strand of an RNA/DNA hydrid 
duplex, thereby generating RNA fragments with 5'-phosphate and 3'-hydroxyl ends (12, 19, 59).  
The mechanism of HIV-1 RT-RNH hydrolysis has been described as a two metal cleavage event 
(Figure 5) (16, 48, 61), where the metal ions have been shown to be essential for RNH activity 
(14).  The first metal ion A is responsible for activating a nucleophilic water molecule hydroxyl 
ion (-OH) and along with the second metal ion B helps stabilizing the transition state 
intermediate.  Metal ion B has further been associated with lowering the activation energy barrier 
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of the transition state by destabilizing the enzyme-substrate ground state through its direct 
interaction with the leaving group from RNH hydrolysis (103).  The four catalytic residues 
coordinate both metal ions, where metal ion A hydrogen bonds with carboxyl oxygens of D443 
and D549, along with the carboxyl oxygen of D498 through a water molecule intermediate, 
while metal ion B hydrogen bonds with the carboxyl oxygens of D443, D498 and E478.  The 
mechanism of RNH hydrolysis begins with metal ion A activating a nucleophilic water molecule 
with the assistance of residue H539.  This causes the hydroxyl ion (OH-) of the water molecule to 
attack, by an SN2 reaction, the 5'-scissile phosphate of the RNA backbone.  While both metal 
ions A and B stabilizing the transition state, whereas metal ion B also interacts with the leaving 
group from hydrolysis, therefore destabilizing the enzyme-substrate ground state and lowering 
the activation energy barrier of the transition state.  The phosphorus then attacks the distal 
oxygen, relative to the 5'-oxygen of the phosphate intermediate causing cleavage of the 
phosphodiester bond, leaving behind a free 5'-phosphate and 3'-hydroxyl ends.   
 
 
 
 
 
Figure 5.  Mechanism of HIV-1 RT-RNH Hydrolysis.  The RNH active site residues (D443,  
E478, D98 and 549) are indicated in green, metal cations are indicated by yellow 
spears and the RNA strand of the RNA/DNA substrate is depicted in pink.  
Acquired from Schultz, J. et al. 2008 (82). 
1.3.3 Mo
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polymerization, such as during pausing events (91, 92).  The polymerase domain can also 
preferentially bind a 5'-recessed end of the RNA strand, resulting in RNA 5'-end directed 
cleavages.  During this mode of RNH cleavages the RNH domain will bind and cleave the RNA 
strand at the 13-19th nucleotide position, relative to the 5'-RNA end (20, 33, 34, 36, 37, 71, 77, 
101).  This mode of RNH cleavage represents a polymerase independent form of RNH cleavage 
and is dependent on the distance of the recessed end (20) and the nucleotide sequence near the 
cleavage site as seen with DNA 3'-end directed mode of cleavages (20, 30, 31, 81).  Furthermore 
the RNA 5'-end directed mode is also dependent on the accessibility of the recessed end, whereas 
this is not seen with the DNA 3'-end directed RNH cleavage mode (80, 81).  The third mode of 
RT-RNH cleavages, non-directed cleavages, results in cleavages internally on the RNA/DNA 
substrate (25, 28, 78, 79, 80).  This mode of cleavage has been shown to depened on the 
substrate sequence (80).  The non-directed mode of cleavage is independent of RT polymerase 
activity as it does not require recessed DNA 3'-end or RNA 5'-end recessing (25, 28, 78, 79, 80) 
as seen with the other two modes. 
 
 
 
 
1.4 CURRENT PROGRESS IN HIV-1 RT-RNH INHIBITORS 
 
 
The critical role of RT in HIV-1 replication makes this enzyme an appealing target for HIV-1 
antiretroviral development.  In fact most of the current clinically approved therapeutics of  HIV-
1 are  antivirals that target RT but only the DNA polymerase activity of the enzyme (98).  These 
antivirals are plagued with inevitable drug resistance due to the virus' high mutation rate and the 
fact that treatment is lifelong.  Therefore, there is a necessity for new antivirals that remain active 
towards current resistant variants of the virus.  HIV RT-RNH is essential for HIV replication 
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(95), yet no therapeutics target RT-RNH activity.  Such therapeutics would certainly remain 
active against current HIV resistant.  However, some progress has been made in the 
identification of small molecules that inhibit the RNH activity of HIV-1 RT, including natural 
products and synthetic compounds.  Binding sites for a few of these inhibitors has been 
determined. 
 
 
 
 
1.4.1 RNHIs with an Undefined Binding Site 
 
 
 
 
1.4.1.1 Illimaquinone 
 
 
 
 
 
 
Figure 7.  Structure of Natural Product RNHI, Illimaquinone 
 
 
 
 The first HIV-1 RNHI identified was in 1990, with the natural marine substance, 
illimaquinone (Figure 7) (62).  Illimaquinone is a secondary metabolite isolated from the red 
sea sponge Smenospongia SP and that has an HIV-1 RT-RNH IC50 within the 15-50 M range 
(62, 67) and to a lesser extent inhibits RT-polymerase activity with an IC50 of approximately 140 
M.  Combination studies with N-ethylmaleimide (NEM, a thiol reactive agent that has been 
CH3
CH3
CH2
CH3
OHO
OH3CO
 12 
 
shown to modify residue C280 of HIV-1 RT (64)) showed the two compounds to be mutually 
exclusive and antagonistic, further subunit independent C280S mutational studies indicates that 
binding occurs specific with the p66 subunit C280 residue, since inhibition with illimaquinone 
was only affected with the p66 C280S mutant.  This suggests that illimaquinone acts as an 
allosteric inhibitor of HIV-1 RT-RNH activity by binding with the p66 thumb subdomain near or 
at residue C280 (63).  Though illimaquinone is not a potent inhibitor of HIV-1 RT-RNH 
activity, it was the first RNHI to be identified and showed that specific inhibition of RT-RNH 
activity is possible.  These discoveries lead to the identification of a cascade of small molecule 
inhibitors, from natural products to specifically synthesized small molecules, as inhibitors of 
HIV-1 RT-RNH activity with and without a defined binding site.  A few other natural products 
have been identified as RNHIs, these compounds tend to lack specificity for targeting RT-RNH 
but nonetheless they have been shown to inhibit the RNH function of RT, as seen in Table 1.   
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Table 1: List of Natural Products HIV-1 RT RNHIs 
 
 
Active Compound Source RT-RNH IC50 (M) 
RT-Pol 
IC50 (M) 
HIV-1 
EC50 
(M)  
Reference 
 
Illimaquinone 
 
  
Smenospongia Sp 
(red sea sponge) 
15-50 140 n.d.¶ 
Loya, S. et al. 1990 (62) 
Loya, S. et al. 1993 (63) 
Min, B.S. et al. 2000 (67) 
 
HP 0.35 
 
 
Cephalosporin 
ceftazidion 
(Bacteralactum 
antibiotic) 
<50* >200* n.d.¶ Hafkemeyer, P. et al. 1991 (39) 
Argentine Plant Extracts 
2I4 
4I4 
 
Achyrocline flaccida 
Phyllanthus sellowianus 
 
3.9±0.9* 
2.4±0.8* 
 
1.0±0.1* 
5.9±1.4* 
 
0.25* 
3.0* 
 
Hnatyszyn, O. et al. 1999 (45) 
Compound 14 
 
Juglans Manshurica 
 
39 0.04 n.d.¶ Min, B.S. et al. 2000 (67) 
Ardimerin digallate  
 
Ardisia japonica 
 
1.5 >50 n.a.^ Tien Da, N. et al. 2007 (94) 
 
1,3,4,5-
Tetragalloylapitol 
 
 
Hylodendron gabunensis  
(Fabaceae plant) 
0.24 n.d.¶ >40 Takada, K. et al. 2007 (93) 
 
Phenolic Gylcosides 
(1) hyemaloside A  
(3) hyemaloside C  
 
 
Eugenia hyemalis L. 
Cambess 
(evergreen tree) 
 
1.46±0.01 
1.19±0.05 
n.d.¶ >20* Bokesch, H.R., et al. 2008 (8) 
Madurahydroxylactones 
3j 
4e 
 
Nonomuraea rubra 
(soil bacterium) 
 
0.69±0.13 
0.78±0.12 
 
n.d.¶ n.d.¶ Marchand, C. et al. 2008 (65) 
 
* units in g/ml not in M 
¶  not determined (n.d.) 
^  was evaluated for HIV-1 antiviral activity and had no activity (n.a.) 
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1.4.1.2 Naphthalenesulfonic Acids 
 
 
 
 
 
 
 
Figure 8.  Structures of Naphthalenesulfonic Acid RNHIs 
 
 
 
Two naphthalenesulfonic acid compounds (compounds 16 and 27, Figure 8) from a small library 
of 25 naphthalenesulfonic acid derivatives have been identified as bi-functional inhibitors of 
HIV-1 RT-RNH and polymerase activity, with a greater potency for RT-polymerase inhibition.  
Both compounds had an RT-RNH IC50 ranging from 15-17uM with an RT RDDP IC50 between 
0.7-4 M and a 7 M IC50 with DDDP activity.  These compounds may chelate metal ions based 
on the presence of the naphthalenesulfonic acid moiety.  This observation suggests the inhibitors 
would have a preference for binding within the polymerase and/or RNH active sites.  Though 
this assumption is plausible, there has been no attempts to prove or exclude metal chelation or 
identify the potential binding site.  These compounds do have antiviral activity against HIV-1 but 
the antiviral properties are most likely the result of targeting virus attachment and/or absorption 
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versus RT activity, since the physiochemical properties of this inhibitor class indicates they 
would be highly charged molecules and unlikely to permeate the cell membrane enabling them to 
work at the level of HIV-1 reverse transcription (68). 
 
 
1.4.1.3  4-chlorophenylhydrazone of Mesoxalic Acid (CPHM) 
 
 
 
Figure 9.  Structure of CPHM 
 
 
 
The compound 4-chlorophenylhydrazone of mesoxalic acid (CPHM or PD1226338, Figure 9) 
was first identified from the screening of a library of 115 compounds for specific HIV-1 RT 
strand transfer inhibition properties (32).  CPHM inhibited HIV-1 RT strand transfer with an 
IC50 of 4.5 M.  Additional analysis of CPHM's ability to directly inhibit RT-RNH activity 
using a gel based RNH cleavage assay resulted in an IC50 of 3 M, suggesting the strand transfer 
inhibition is mainly the result of RT-RNH inhibition and indeed this was further supported since 
CPHM was unable to inhibit RT-polymerase activity up to 75 M.  CPHM's RNH inhibition 
principally targets RNH polymerase independent cleavages, since experiments in the absence of 
dNTPs had an RT-RNH IC50 of 3.0 M, similar to the strand transfer IC50 of 2.2 M in the 
presence of a HIV-1 nucleocapsid.  The dicarboxylic acid group of CPHM has been shown to be 
involved in metal chelation with Mg+2 and essential for RT-RNH inhibition, since substitution of 
one or two of  the dicarboxylic acid group's hydroxyls with a methyl caused the RT-RNH IC50 to 
increase substantial to 30-200 M (17).  It was further shown that CPHM is a moderately 
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specific inhibitor of HIV-1 RT since it was unable to inhibit MLuV RT, AMV RT, Klenow 
Fragment DNA polymerase, and T4 DNA polymerase up to 68 M, but was able to inhibit E. 
coli RNH activity with an IC50 of 2.6 ± 0.6 M (17).  It can be proposed but not concluded that 
CPHM inhibits by binding to the RT-RNH active site though metal chelation, since this RNHI 
can also inhibit the structurally similar E. coli RNH but in order to definitely conclude binding 
within the RNH active site more direct evidence is required. 
 
 
 
 
1.4.1.4  N-Hydroxymides and N- Hydroxyisoquinolines  
 
     
 
 
 
 
Figure 10 .  Structures of N-Hydroxymide and N- Hydroxyisoquinolines RNHIs 
 
  
 
N-hydroxymide compounds were designed to directly interact with a two metal ion active site, 
such as HIV-1 RT-RNH, where the three oxygen atoms would mimic the catalytic residue 
geometry required for metal ion interaction (57).  Compound 1 (Figure 10) was the most potent 
compound with an RT-RNH IC50 of 1 M and an RT-polymerase IC50 of 40 M, while being 
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unable to inhibit E. coli RNH, influenza and T7 DNA polymerase activity.  The N-hydroxyl 
functionality was essential for inhibition potency since replacing the hydroxyl with either a 
methoxy or an amino group resulted in a complete loss of RT-RNH inhibition.  Phenyl group 
substituents such as chloride (-Cl) enhanced potency and selectivity for RT-RNH inhibition. 
Compound 7 (Figure 10) was the most potent compound with an RT-RNH IC50 of 0.3M.  
Interestingly, NMR studies have indicated that RT-RNH inhibition by N-hydroxymides is metal 
dependent and requires the enol form of the inhibitor for binding to occur.  Compounds 1 and 7 
inhibited an HIV-1 RNH domain fragment with an IC50 of 0.43 M and 0.38 M, respectively.  
Protein intrinsic tryptophan quench studies using the RNH domain fragment showed compound 
1 to have a Kd of 2.32x10-5 M with a 1:1 binding ratio.  This binding was assumed to occur near 
the RNH active site, since a gradual blue shift peak was seen with residue W123 near the RNH 
active site (40).  The putative inhibition mechanism for N-hydroximides thus involves metal 
chelation with the active site metal ions.  
N-Hydroxyisoquinolines are a class of metal chelating compounds that were derived from 
the N-hydroxymides pharmacophore and are bi-functional inhibitors of HIV-1 RT-RNH activity 
and IN.  Initial IC50 for IN inhibition ranged from 0.09-19 M, while with RT-RNH the IC50 
ranged from 5.7-96 M, depending on the substitutions made to the 7'-position of the N-
hydroximide functional group (6).  None of the compounds inhibited RT-polymerase activity up 
to 50 M.  The initial lead compound, 1 (Figure 10) had an RT-RNH IC50 of 5.9 ± 1.4 M and 
6.3 ± 2.6 M IC50 with IN.  Further structural modification of the 7'-position of compound 1 
enhanced IN inhibition but had little to no effect on RT-RNH inhibition.  The two best dual 
inhibitors of RT-RNH and IN activity were compounds 6s and 6j (Figure 10), with an RNH IC50 
of 6.6 ± 0.5 M and IN IC50 of 0.65 ± 0.3M for compound 6s.  Compound 6j had an RNH IC50 
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of 5.7 ± 1.5 M and an IN IC50 of 1.24 ± 1.04 M, and was the only compound with antiviral 
activity against HIV (EC50 of 22 M and a CC50 of 84 M) (6).  Addition of an electron 
withdrawing methoxycarboonyl group to the 4’-position of compound 1 (compound 3, Figure 
10), intended to enhance metal chelation, substantially improved RNH inhibition (61 ± 5 nM 
IC50) (7).  This modification had little to no effect on IN inhibition (5 ± 0.6 M IC50) and slightly 
enhancing antiviral activity with (EC50 of 13 ± 5 M and CC50 61 ± 3 M).  The addition of an 
electron-withdrawing group at the 4'-position stabilized the enol form of the N-hydroximide 
functional group, therefore enhancing metal chelation, since the enolic form of these compounds 
been shown to be responsible for the ability to chelate two metal ions (6, 7).  Compounds 
designed from N-hydroxyisoquinolines inhibitor class are unfavorable candidate for drug 
development considering the two compounds with antiviral activity had only a selectivity index 
around 4.  However, these compounds are good examples for showing how HIV-1 RT-RNH and 
IN inhibition activity might be modified through metal chelation properties.   
 
1.4.1.5 Diketo Acids (DKA) 
 
 
 
 
 
 
 
Figure 11.  Structure of DKA RNHIs 
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The first compound from the diketo acid class of compounds to be described  as an RNHI was 4-
[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid (BTDBA) (Figure 11) with an RT-RNH 
IC50 of 3.2 ± 1.7 M and no RT-polymerase inhibition up to 50 M.  This compound has also 
been shown to directly inhibit and bind with a stoichiometry of 1:1 to a catalytically active RT-
RNH domain fragment with a Kd of 8.9 ± 3.5 M and IC50 of 4.7 ±3.2 M.  These binding 
studies also indicated that the inhibitor does not require the presence of the substrate in order to 
bind with the enzyme (83).  BTDBA appears to have some specificity for RT-RNH inhibition, 
since it was unable to inhibit a structurally similar enzyme, E. coli RNH.  Unfortunately, 
BTDBA does not have any HIV-1 antiviral activity.  Mutational studies with a D185N-RT (a 
lethal polymerase active site mutation that has no effect on RNH activity) indicates that BTDBA 
does not bind within the polymerase active site, since there was no significant loss in RNH 
inhibition with this mutation having an (IC50 of 8.8±1.8M IC50).  Based on both the mutational 
studies with D185N-RT, the metal dependence for direct inhibition and binding with the p15-EC 
RT RNH domain fragment, it is plausible that BTDBA binds within in the RNH active site, 
directly interacting with the active site metal ions.  The ability of BTDBA to inhibit HIV-1 IN 
activity with an IC50 of 1.9 M similar to the RT-RNH IC50 (3.2 ± 1.7 M), also supports 
binding within the RNH active site since both enzymes have similar active sites (83).  
Compounds from the same structural class of BTDBA inhibit HIV-1 IN through a metal 
sequestration mechanism, suggesting BTDBA could inhibit through the same metal chelating 
mechanism as seen with the other thiophene diketo acid compounds (38, 41).  However, there 
have been no published studies directly showing metal chelation with BTDBA. 
 A derivative of BTDBA, 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-
hexenoic acid ethyl ester (RDS-1643, Figure 11) was originally designed as an HIV-1 IN 
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inhibitor and later evaluated as an RT RNHI (97), since both enzymes have similar active sites.  
This compound is much less potent as an RNHI compared to BTDBA with an RT-RNH IC50 of 
13 ± 4 M but it did have antiviral activity against HIV-1 with MT4 cells, unlike its predecessor 
BTDBA (EC50 of 14 ± 2 M and a CC50 of 63 ± 4 M).  Additionally, RDS-1643 was also active 
against non-nucleoside reverse transcriptase inhibitor (NNRTI of RT polymerase activity) 
resistant strains of HIV-1, including Y181C-RT, K103N/Y181C-RT and K103R/V179D/P225H-
RT indicating a potential of this inhibitor class for being able to inhibit clinically relevant 
resistant variants of HIV-1.  Interestingly,  this compound was unable to inhibit HIV-1 IN up to 
~95 M, while having no polymerase inhibition against HIV-1 RT and AMV-RT activities, 
along with no inhibition against E. coli RNH activity up to 100 M.  These results suggest RDS-
1643 to be a more specific inhibitor targeting RT-RNH activity compared to BTDBA.  Kinetic 
studies using Michaelis-Menton and Segal assumptions showed that RDS-1643 is a non-
competitive and reversible RT-RNH inhibitor with a KI of 17 M.  As with BTDBA, RDS-
1643's RT-RNH inhibition is independent of substrate binding, since time of addition 
experiments had no change in inhibitory properties.  Although no direct studies with BTDBA 
have shown metal chelation, UV-Vis experiments in the presence of MgCl2 with RDS-1643 
confirm DKA's are metal chelators.  Combination studies with RDS-1643 and nevirapine or 
efavirenz (NNRTIs) had no effect on RT-RNH and polymerase inhibition, suggesting RDS-1643 
binding is unlikely to occur in or near the non-nucleoside reverse transcriptase inhibitor binding 
pocket (NNRTIBP).  Additional studies with NNRTI resistant mutant further supports RDS-1643 
inability to bind near or within the NNRTIBP, while the metal chelating properties of RDS-1643 
further suggest DKA binding occurs via metal chelation with the RNH active site metal ions. 
 
 
 21 
 
1.4.1.6 Vinylogous Ureas  
 
 
 
 
 
 
Figure 12.  Structures of Vinylogous Urea RNHIs 
 
 
The screening of a library containing ~230,000 natural and synthetic compounds identified 
vinylogous ureas as RNHIs.  Two compounds (Figure 12), NSC727447 (compound 1) and 
NSC727448 (compound 2) showed the best inhibition properties.  Both compounds were 
monofunctional inhibitors of RT-RNH activity.  Compound 1 inhibited HIV-1 RT-RNH (2.0 M 
IC50), HIV-2 RT-RNH (2.5 M IC50), E. coli RNH (100 M IC50) Human RNH (10.6 M IC50) 
(99), and had antiviral activity against HIV-1 (4.3 M EC50i and 19.9 M CC50) (15).  
Compound 2 inhibited HIV-1 RT-RNH (3.2 M IC50), HIV-2 RT-RNH (5 M IC50), E. coli 
RNH (73 M IC50), human RNH (29 M IC50) (99) and no antiviral activity against HIV-1.  
Various studies suggested that vinylogous ureas bind outside of the RNH active site. MALDI-
TOF and ESI-TOF MS/MS studies fallowing N-hydroxysuccinimidyl-biotin treatment and 
                                                 
i Antiviral activity was never evaluated to be the result of directly targeting reverse transcriptase (15).  
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tryptic digestion experiments, suggest that compound 1 binds within or near residues K281 and 
C280, since compound 1 protected K281 and C280 modification by N- hydroxysuccinimide.   
 Further studies (15) involving 3'-CONH2 and cycloalkane modification of the thiophene 
ring of the vinylogous urea pharmacophore resulted in an additional 22 derivatives.  Evaluation 
of RT-RNH activity based on the structural modifications indicated that the size of the 
cycloalkane ring is important, where a ring size that is too small or too large negatively affects 
RT-RNH inhibition, suggesting that binding is dependent on hydrophobic interactions and/or pi-
pi stacking between the inhibitor and protein residues.  Additional modifications of compound 
1's 2'-NH2 functional group with a 2'-phenoxy acetylamino (6.9 M RT-RNH IC50, compound 8) 
or 2'-furanoyl with a 4'-ethoxyphen (4.2 M RT-RNH IC50, compound 9) indicates the furanoyl 
group is highly significant for RT-RNH inhibition, since replacement of furanoyl with a phenyl 
group causes a complete loss in RT-RNH inhibition (>500 M RT-RNH IC50, compound 10).  
The significance of the furanoyl group suggests its oxygen may be involved in hydrogen bonding 
with protein residues in order to enhance RT-RNH inhibition.  Structural modifications of 
compound 2  by introducing either a rigid or flexible bulky aryl substitutions resulted in the most 
active vinylogous urea RNHI, compounds 14 (1.3 M RT-RNH IC50, Figure 12) and 16 (0.85 
M RT-RNH IC50, Figure 12).  These results suggest that the increase in thiophene ring rigidity 
with the formation of a pyrimidine ring from the 2'-NH2 and 3'-CONH2 group largely enhances 
RT-RNH inhibition, whereas increasing the flexibility of the aryl had a negative effect on 
inhibition.  Substitution of compound 16's 4'-NO2 functional group with a -OCH3 group caused a 
complete loss in RT-RNH inhibition (>50 M RT-RNH IC50), suggesting that the 4'-NO2 group 
may be involved in hydrogen bonding (15).   
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 Molecular modeling studies indicated the binding location of compound 1 to reside 
within the interface between the p51 and RNH domain, where the cycloalkane ring occupies a 
small binding pocket formed by G541 (RNH domain residues), C280 (p51 residue) and R284 
(p51 residue).  The most favorable pose had the thiophene ring making three hydrogen bonds 
with protein residues V276 (p51 residue), K275 (p51 residue) and H539 (RNH domain residue). 
In addition the carbonyl of residue V276 and side chain amine of residue K275 are hydrogen 
bonding with the 3'-CONH2 functional group, along with the backbone carbonyl-oxygen of 
residue H539 hydrogen bonding with the thiophene ring's 2'-NH2 functional group.  Molecular 
modeling studies with compound 16, resulted in the docking within the same binding pocket as 
compound 1 with a slightly different orientation, in which the thiophene ring's 4'-NO2 group 
makes a potential 4 Å hydrogen bond with residue R284 (p51 residue) and the planar benzene 
ring resides within the same hydrophobic pocket of compounds 1's cycloalkane (15).  
 
 
 
 
1.4.1.7  5-nitro-furan-2-carboxylic carbamoylmethyl ester (NACME) 
 
 
 
 
Figure 13.  Structures of NACME RNHIs 
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5-nitro-furan-2-carboxylic carbamoylmethyl ester (NACME) RNHIs were identified during the 
screening of a library of 20,000 compounds for potential RT-RNH inhibitors.  Of the NACME 
compounds in the library, 32 (35%) inhibited HIV-1 RT-RNH activity.  The two most potent 
compounds were 5-nitro-furan-2-carboxylic acid adamantan-1-carbamoylmethylester 
(compound 1, Figure 13) and 5-nitro-furan-2-carboxylicacid [[4-(4-bromo-phenyl)-thiazol-2-
yl]-(tetrahydro-furan-2-ylmethyl)-carbamoyl]-methyl ester) (compound 2, Figure 13).  Both 
compounds were evaluated for an ability to inhibit HIV-1 RT from different viral clades.  
Compound 1 inhibit RT of all three major HIV-1 clades (clade B, C and CRFO1 A-E) with IC50 
values of 29.6 ± 9.2 M, 26.5 ± 15.0 M, and 3.8 ± 1.5 M, respectively.  Compound 2 was also 
able to inhibit all three clades as well with an RT-RNH IC50 of 26.7 ± 13.5 M (clade B), 32.2 ± 
0.5 M (clade C), and 2.6 ± 1.8 M (clade CRFO1 A_E).  Both compounds had no effect on 
HIV-1 RT dependent DNA polymerase activity, HIV-1 IN activity, E. coli RNH activity or 
human RNH, but they were able to inhibit the RNH activity of MLV-RT (~9 M IC50).  The 
reported antiviral properties seen with compounds 1 and 2 (EC50 ~23-25 M) was likely the 
result of compound cytotoxicity, as the in vitro selectivity index was low (29).  Molecular 
modeling studies suggested that the nitro-furan group interacts with RNH active site metal 
cations and H539, while the amide carbonyl-oxygen interacts with residue S553.   
 Additional synthesis of NACME derivatives evaluated the ester linker, nitro-furan group 
and hydrophobic moieties for RT-RNH inhibition (102).  Compounds 10 and 40 (Figure 13) 
were the most potent derivatives with an RT-RNH IC50 of 0.9 M and 2.8 M, respectively.  
Substitution of the nitro-furan group completely eliminated inhibitor activity.  It is possible that 
the nitro-furan oxygens are capable of metal chelation, since the nitro-furan-carboxylic acid 
compounds are structurally similar to active site metal chelating RNHIs, β-thujaplicinol 
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(subsection 1.4.2.1) and pyrimidinol carboxylic acid (subsection 1.4.2.2)  (5, 44, 56).  The ester 
linkage between the nitro-furan group and hydrophobic moiety was also replaced with an amide 
group in order to make the compounds more favorable as drug candidates, since an ester within 
the human body would be rapidly digested by esterase causing drug concentrations to be 
depleted rapidly.  Unfortunately, this resulted in a loss of inhibitor potency. 
 
 
 
 
1.4.1.8 Alizarines  
 
 
 
 
 
 
Figure 14.  Structures of Alizarine RNHIs 
 
 
 
Alizarine emodine (Figure 14) was first identified as an RT-polymerase inhibitor (IC50 of 79 
M) and was unable to inhibit RNH activity (55).  Alizarine emodine derivatives with 
substitutions at the 1' and 2'-positions of the alizarine ring were synthesized.  The most potent 
compounds were K-49 and KNA-53 (Figure 14), with and RT-RNH IC50 of 13 ± 3 M and 21 ± 
2 M, along with a RT-polymerase IC50 of 12 ± 3 M and 5 ± 2 M, respectively.  Replacement 
a distal bromide (Br) of KNA-53 with a phenyl group, resulted in a complete abrogation of RT-
RNH inhibition up to 100 M and did not affect RT-polymerase inhibition.  Addition of two 
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phenylketo groups at both R1 and R2 positions, as seen with compound K-49, resulted in the most 
potent RT-RNH inhibition from this class of RNHIs.  All of the alizarine derivatives, including 
K49 and KNA-53 had no antiviral activity against HIV-1.  Michaelis-Menton kinetic studies with 
K-49 showed that RT-RNH inhibition is non-competitive with respect to the substrate, having a 
KI of 7 M, Km of 1.5 nM and a Kcat of 0.82 s-1.  K-49 and KNA-53 did not bind to the RNH 
domain fragment and showed no metal dependence for RT-RNH inhibition, suggesting the 
inhibitors are not RNH active site binders.   
 
 
 
 
1.4.2 RNHIs with a Known Binding Site 
 
 
 
 
1.4.2.1 Tropolones 
 
 
 
 
 
Figure 15.  Structures of Tropolones RNHIs 
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Tropolones were first identified as an RNHI during the screening of a library of natural products 
(10), in which β-thujaplicinol (Figure 15) was the most active RNHI.  β-thujaplicinol inhibited 
RNH activity with an IC50 of 0.21 ± 0.03 M (HIV-1), 0.77 ± 0.08 M (HIV-2) and 5.7 M 
(Human RNH), and was inactive against HIV-1 RT-polymerase and E. coli RNH activity.  All of 
the tropolones evaluated had no antiviral activity.  Tropolones, including β-thujaplicin (> 100 
M IC50, Figure 14) and α-thujaplicinol (50 M IC50, Figure 14) were inactive or less potent as 
an HIV-1 RT-RNHI compared to β-thujaplicinol.  Structural comparison of β-thujaplicinol and 
β-thujaplicin indicated that the 7'-hydroxyl of β-thujaplicinol is essential for potent RT-RNH 
inhibition, while comparison with α-thujaplicinol indicates an α-hydroxyl substituent is less 
active than a compound with a β-hydroxyl (β-thujaplicinol).  Michaelis-Menton kinetic studies 
suggested the type of inhibition was mixed, in which non-linear fitting confirmed these results 
with both β-thujaplicinol and manicol (Figure 15).  These results indicate that the tropolone 
inhibitors can bind the free enzyme or binary complex of RT with the substrate near an active 
site (10).  Recent X-ray crystal structure with HIV-1 RT (2.80Å) and a His-tag RNH domain 
fragment (2.04Å) revealed that β-thujaplicinol does indeed bind within the RNH active site and 
chelates both metal cations. All three oxygens of tropolone ring of β-thujaplicinol coordinates 
both metal cations (Mn+2) in both co-crystal structures.  Ionic or hydrogen bonds are made with 
metal cation B and residues E478, D498, H539, while metal cation A interacts with residue D549 
and the hydroxyl group of the inhibitor forms a salt bridge with residue R557.  The active site 
binding is perhaps inconsistent with the non-competitive inhibition.  However, it has been 
proposed that the nucleic acid substrate may sterically restrict the inhibitor within the bound state 
and hinder dissociation of the inhibitor (44), rather than the inhibitor binding to the substrate, as 
previous studies showed the inhibitors are unable to bind to an RNA/DNA substrate (10).  
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1.4.2.2  Pyrimidinol Carboxylic Acids  
 
 
 
 
 
 
Figure 16.  Structures of Pyrimidinol Carboxylic Acid RNHIs 
 
 
 
The pyrimidinol carboxylic acid compounds were identified as RNHIs while designing a 
compound based on the diketo acid compound BTDBA (subsection 1.4.1.4) with a more stable 
tautomeric scaffold (56).  The 2'-phenyl with a methylene linker, as seen with compound 7 (2.5 
M RT-RNH IC50, Figure 16) was shown to be highly significant for RT-RNH inhibition, since 
2'-modifications reduced RT-RNH inhibition.  Substitutions added to the phenyl ring of 
compound 7, such as the addition of two chloro groups (compound 9), enhanced RT-RNH 
inhibition (IC50 of 1.45 ± 0.4 M, Figure 16).  During pre-steady state RNH cleavages kinetic 
analysis, compound 9 was shown to be metal dependent for RT-RNH inhibition, since the initial 
burst rate of catalysis was significantly inhibited under conditions of pre-incubation with the 
enzyme-inhibitor in the presence of metals; enzyme-inhibitor pre-incubation in the absence of 
metals was unable to inhibit RNH catalysis.  These observations further support the metal 
dependent behavior of compound 9.  The compounds were further unable to inhibit human-RNH 
and had no HIV-1 antiviral activity with MT-4 cells.  An X-ray crystal structure of compound 9 
with the p15-EC RT RNH domain fragment (1.7Å), showed the inhibitor chelating RNH active 
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site metal cations.  The carboxylate oxygen of compound 9 coordinates with metal ion B, while 
the oxygens of the two phenolic groups coordinate metal ion A.  In addition, the 2'-phenyl 
substitution interacts with the imidazole ring of H539, consistent with the improved potency seen 
with the methylene linker.  The center of the phenyl ring is 3.8 Å from the  imidazole ring of 
H539 and makes an edge-on-pi interaction with H539 (56).  The X-ray structure of compound 9 
chelating active site metal ions and its metal dependent behavior, suggest that pyrimidinol 
carboxylic acids mechanism of inhibition is the result of RNH active site metal chelation.  
 
 
 
1.4.2.3  N-hydroxy Naphthyridinones 
 
 
 
 
 
Figure 17.  Structure of N-hydroxy Naphthyridinone RNHIs 
 
 
 
N-hydroxy naphthyridinone RNHIs were first developed as HIV-1 IN inhibitors (42).  A recent 
study showed three N-hydroxy naphthyridinone RNHIs,  MK1 (IC50 of 0.11 M and EC50 of 2.7 
± 0.2 M), MK2 (IC50 of 0.12 M and EC50 of 3 M) and MK3 (IC50 of 0.22 M and EC50 of 
9M) (Figure 17) bound to the RNH active site and the N-hydroxy naphthyridinone core 
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chelates the metal ions (90, 100).  These specific compounds were chosen for X-ray 
crystallography studies since previous studies indicated no preference for binding within either 
the RNH or IN active sites (42), suggesting they have the greatest probability for metal chelation.  
All three compounds were unable to inhibit RT-polymerase activity and though they have 
antiviral activity against HIV-1 no evidence has been shown to prove the antiviral activity is the 
result of targeting reverse transcription during in vivo studies.  
 MK1 and MK2 x-ray crystal structures with full length RT at 2.80 Å and 2.23 Å shows 
that the RNH active site residues D443, E478, D498 and D549 form the binding site, in which 
both compounds have the same orientations with the hydroxyl group coordinating with the active 
site metal ions and the oxygens of the naphthyridinone nitrogen providing support.  Metal ion A 
is coordinated by the carboxyl oxygens of D443, E478, D498 and the central hydroxyl and 
flanking nitrogen of compounds MK1 and MK2, while metal ion B is coordinated by the residue-
carbonyls of D443, D549 and the central hydroxyl of both compounds.  Residues H539 is within 
2.7 Å of hydrogen bonding distance from the naphthyridinone-oxygen, along with 3.2 Å and 3.3 
Å of the two carboxylate-oxygen's of D549, while also within 3.0 Å from both compound's 
carboxylate-oxygen.  Overlaying of the co-crystal structure of MK2 with both co-crystal 
structures of β-thujaplicinol (subsection 1.4.2.1) or pyrimidinol carboxylic acid (subsection 
1.4.2.2) with full length RT shows all three RNHIs have similar orientations within the same 
binding site and have group extensions pointing towards residues H539, indicating the 
significance of interactions with H539 for RT-RNH inhibition when bound to the RT-RNH 
active site (90).  The co-crystal structure of MK3 and full length RT resulted in the RNHI 
binding near the NNRTIBP as opposed to binding within the RNH domain.  MK3 bound within 
the polymerase domain's hydrophobic binding pocket (adjacent to the NNRTIBP) was formed by 
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residues L100, V108, Y181, Y183, D186, L187, K223, F227, L228, W229 and L234.  The 
diethylamiophenoxy group of MK3 seems to lead binding within the site as opposed to the 
naphthyridinone core, as seen with MK1 and MK2.  The two different binding locations of MK1 
and MK2 versus MK3's polymerase binding site suggest that the N-hydroxy naphthyridinone 
class of compounds can bind two different locations.  The binding site of MK3 near the 
NNRTIBP is very similar the binding of DHBNH (an N-acylhydrazone, subsection 1.4.2.4) 
within the polymerase domain (43).  It is plausible that MK3 can also bind within the RNH 
active site, considering the compound has been shown to be metal dependent for RT-RNH 
inhibition.  It is possible that crystal packing with full length RT and the larger size of MK3, 
prevented binding within the RNH domain.  MK3 was able to bind and chelate metal ions within 
the RNH domain of an isolated RNH domain fragment in a similar manner to MK1 and MK2 
(90).  MK3 bound the active site of the isolated RNH domain fragment has a slight difference in 
orientation compared to MK1 and MK2, in which the phenyl ring of MK3 also packs against 
residue Q500 (90). 
 Derivatives of MK1 were created with the intention of enhancing ligand contacts with the 
RNH active site, through lipophilic modification of the 4'-position of the naphthyridinone core 
(100).  The most potent compound was compound 13 (Figure 17), with an homolongation of the 
benzene linker and a meta bi-phenyl group, containing a substituted para aminomethyl group on 
the distal phenyl ring with the intention of enhancing inhibitor-protein contacts and solubility.  
Compound 13 had and RT-RNH IC50 of 45 ± 20 nM and was able to inhibit RT-polymerase 
activity with a 13 ± 1.3 M IC50, unlike its predecessor.  Compound 13 had an enhancement in 
antiviral activity against HIV-1 with an EC50 of 190 ± 120 nM and a CC50 of 3.3 ± 2.3 M, 
resulting in a favorable selectivity index of 57.5.  However, the antiviral activity has not been 
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identified to work at the level of HIV-1 reverse transcription.  Attempts were made to obtain  x-
ray crystal structure of compound 13 with full length RT, along with molecular docking studies 
but these attempts were unsuccessful (100).  
 
 
 
 
1.4.2.4  N-Acylhydrazones 
 
 
                         
                       
 
 
 
 Figure 18.  Structure of N-acylhydrazone RNHIs 
 
 
 
N-acylhydrazones were the first RNHIs with antiviral activity (9).  The first N-acylhydrazone 
compound described was N-(4-tert-Butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone 
(BBNH), Figure 18.  BBNH is a bi-functional inhibitor of HIV-1 RT RNH and polymerase 
activity with a 3.5 M and 0.8-34 M IC50 (depending on template/primer), respectively.  HIV-1 
antiviral activity of BBNH with PBMC and MT4 cells had an EC50 of 1.5 M and 5 M, 
respectively.  RT-RNH inhibition was time dependent according to the length of enzyme-
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inhibitor pre-incubation and required the presence of metal ions.  RT-RNH inhibition was 
reversible and competitive with respect to the RNA/DNA substrate during kinetic studies, while 
also being moderately specific for HIV-1 RT-RNH inhibition.  BBNH was able to inhibit E. coli 
RNH (2.7 ± 0.9 M) and MLV RT-RNH activity (0.8 ± 0.2 M), while being unable to inhibit 
RNH activity of HIV-2, AMV and bovine pancreatic RNase A.  RT-polymerase inhibition was 
reversible and mixed-type with both the substrate and dNTP.  In fact, the polymerase kinetic 
inhibition profile was identical to the polymerase kinetic inhibition profile of known NNRTIs.  
The polymerase inhibition of BBNH was specific to HIV-1 RT, since it was unable to inhibit 
HIV-2, AMV, MLV, Taq DNA Polymerase, Klenow DNA polymerase, HeLa cell nuclear 
extracts and DNA polymerase activities up to 50 M.  BBNH retained in vitro RT-RNH and 
polymerase inhibition potency with clinically relevant RT resistant mutants, including K103N, 
Y181C, Y181I, Y188H and Y188L.  Combination studies with known NNRTIs and photo-
labeling 9-ANii had no affect on RT-RNH inhibition by BBNH, suggesting that BBNH has a 
potential for binding a location separate from the NNRTIBP.  This is further reinforced by the 
fact that RT-RNH inhibition of BBNH is metal dependent and therefore suggesting binding 
within the an active site involving metal chelation.  In addition, the ability to protect RT-
polymerase activity dose dependently from being deactivated during 9-AN photo-labeling 
studies, while also being unable to inhibit the polymerase activity of other enzymes that lack the 
NNRTIBP, such as HIV-2 (9), suggest that BBNH is able to bind an additional site independent 
of an active site.  These observations suggest that BBNH binds two spatially distinct sites, within 
an active site by metal chelation and at or near the NNRTIBP.  
                                                 
ii A photoactive analogue of nevirapine that permanently blocks the NNRTIBP (9).  
 34 
 
Molecular modeling studies showed BBNH docked within the RNH active site, in which 
the naphthyl benzene ring of the compound makes pi-pi stacking interaction with residue Y501 
(3).  The hydrazone amide and carbonyl groups are making further hydrogen bonds with the 
active site metal ions.  A derivative compound of BBNH lacking a second naphthyl benzene 
ring, BBSH indicated the second naphthyl benzene ring for pi-pi stacking is significant for RT-
RNH inhibition.  This was evident, since BBSH had a loss in RT-RNH inhibition (2.5 ± 0.4 M 
IC50) while retaining its RT-polymerase inhibition.  Additional mutational studies with Y501x 
(W and R) confirm that BBNH must have significant contact with residue Y501, since RT-RNH 
inhibition was reduced or completely abrogated and RT-polymerase inhibition was unaffected by 
these mutations (3).  BBNH was the first compound to display bi-functional inhibition against 
RT-RNH and polymerase activities through a mechanism that suggests binding within two 
spatially distinct sites within the polymerase and RNH domains.  An extended study with BBNH 
showed that its binding with HIV-1 RT impacts heterodimer stability and causes dimer 
dissociation (84), suggesting its mechanism of inhibition is the result of the heterodimer 
dissociation of RT.   
 A BBNH derivative, dihydroxy benzoyl naphthyl hydrazone (DHBNH, Figure 18) has 
been described in the literature (43).  DHBNH was created to prevent metal cation chelation, 
since the hydroxyl of the naphthyl ring was replaced with a methoxy group.  DHBNH is a 
monofunctional inhibitor of RT-RNH activity (IC50 of 0.5 ± 0.2 M) and is unable to inhibit RT-
polymerase activity, unlike its predecessor BBNH.  DHBNH is a much wearker inhibitor of the 
p15-EC RT RNH domain fragment (IC50 of 18.5 ± 3.4 M), suggesting that the compound may 
not bind to the RNH active site.  An X-ray crystal structure of DHBNH with full length RT (3.15 
Å) shows the inhibitor bound within a site ~3.5 Å away from the polymerase active site near the 
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NNRTIBP.  The benzyl ring partially enters the NNRTIBP and interacts with NNRTIBP residue 
W229, while the naphthyl ring is oriented near the polymerase active site and primer grip region.  
The binding site of the inhibitor is formed by residues V108, L187, Y188, K223, F227, and 
L228, in which residue-inhibitor contacts occur through main chain β-carbons, suggesting that 
DHBNH may retain activity against HIV-1 NNRTI resistant strains.  Additional studies have 
shown that the inhibitor remains active against common NNRTI resistant RT mutants, including 
Y188L.  DHBNH also retains antiviral activity against NNRTI resistant strains of HIV-1, 
including RT mutant strains such as Y181C (nevirapine resistant), Y106A/Y181C (UC781 
resistant), L100I/K103N (efavirenz resistant) and D67N/K70R/T215F/K219Q (AZT resistant).  
Real time PCR experiments showed that the antiviral activity of DHBNH (5.5 ± 1.7 M EC50 
with HIV-1, CC50 > 100 M) works at the level of reverse transcription by inhibiting the 
initiation of HIV-1 reverse transcription.  In addition, comparison of DHBNH-RT with the co-
crystal structure of CP-94-07-RT, have a very similar protein conformation, therefore supporting 
these PCR results since inhibitor CP-94-07 inhibits the initiation of transfer-RNA primed DNA 
synthesis.  The co-crystal structure of DHBNH led to the proposal that the bound inhibitor would 
cause structural changes in the polymerase primer grip and thumb domain and would alter the 
trajectory of the P/T and prevent proper orientation of the substrate with the RNH active site, 
thereby inhibiting RNH hydrolysis.  Superposing of RT-DHBNH crystal structure with and RT-
RNA/DNA co-crystal structure further suggest that DHBNH cannot prevent substrate or dNTP 
from binding, and in fact kinetic studies with DHBNH indicates the type of RT-RNH inhibition 
is non-competitive with the substrate.  Though the crystal structure of DHBNH bound to RT 
results in a binding site within the polymerase domain, there is still a possibility of a second 
binding site within the RNH domain.  The potential for a second binding site of DHBNH is 
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supported by the fact that its RT-RNH inhibition is unaffected in a presence of excess of (20 M) 
nevirapine (43).  Furthermore, superposition of DHBNH-RT and nevirapine-RT crystal 
structures, suggest that nevirapine (NNRTI) would cause residue Y188 to rotate and clash with 
the benzyl ring of DHBNH and prevent the inhibitor from binding.  Therefore, it is plausible that 
DHBNH was unable to bind within the RNH domain due to crystal packing, causing the 
inhibitor to be sterically excluding from binding within the RNH domain, as seen with N-
hydroxy naphthyridinone compound (MK3, subsection 1.4.2.3) with full length RT (90).  
 Recently, two derivatives of DHBNH have been described (35), in which the fused 
naphthyl ring of DHBNH was replaced with a flexible extended biphenyl system that has a 
carboxylate group in the distal phenyl ring with either a dihydroxy (BHMP03) or trihydroxy 
(BHMP07) benzyl substituents (Figure 18).  The carboxylate group was added in order to make 
ionic interactions with the polymerase domain residue K223 and therefore enhancing inhibitor-
protein contacts and subsequently enhancing inhibitor potency.  BHMP03 and BHMP07 are 
identical in structure expect for an added third hydroxyl to the distal phenyl ring with BHMP07, 
which seems to be responsible for the added ability to inhibit RT-polymerase activity as well as 
RT-RNH activity, unlike the RT-RNH monofunctional inhibitor BHMP03.  Indeed BHMP07 is 
able to inhibit RT-RNH activity with an IC50 of 0.2 ± 0.1 M and RT-polymerase activity with 
an IC50 of 0.3 ± 0.2 M, along with inhibiting the p15-EC RT RNH domain fragment (IC50 of 
0.8 ± 0.06 M).  BHMP03 is unable to inhibit the RNH activity of the fragment but is able to 
bind with the enzyme (Kd of 23.1 M),   along with inhibiting the RNH activity of full length RT 
(IC50 of 0.4 ± 0.2 M).  BHMP07 had a greater binding affinity with the p15-EC RT RNH 
domain fragment with a Kd of 5.3M.  Solution NMR 1H-15N HSQC chemical shift binding 
studies of the interaction of BHMP07 with the p15-EC RT RNH domain fragment, showed  that 
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BHMP07 causes chemical shift perturbation of residues 72-110, of which residues 81-104 are 
residues that make up the extended E. coli helix-loop to restores activity to the enzyme.  
Supposition of the p15-EC RT RNH domain fragment NMR chemical shift structure with the X-
ray crystal structure of full length RT (PDB: 2I5J) suggest that the extended E. coli loop mimics 
the inter subunit interface between the p51 subunit and the RNH domain of the p66 subunit and 
therefore acting like a substrate handle.  HSQC titration experiment with BHMP07 and the p15-
EC RT RNH domain fragment in a ratio of 1:4 (protein: ligand) resulted in a Kd of 142.7 ± 35.7 
mM in the absence Mg+2 and a Kd of 392.0 ± 69.9 M in the presence Mg+2.  The NMR 
dissociation constants (Kd) indicates that BHMP07 has a better binding affinity with the p15-EC 
RT RNH domain fragment in the absence of metal cation and suggest that the inhibitor is not  
metal dependent for RNH inhibition.  Mutational studies with N-acylhydrazones (including 
BHMP03, BHMP07 and DHBNH) resulted in a reduction or loss in RT-RNH inhibition with 
the amino acid substitutions A502G/F and A502G/F+D256G (35).  DHBNH's loss of RT-RNH 
inhibition with mutated RNH residues, along with the proposed NMR binding site suggest that 
DHBNH has a second binding site within the RNH domain between the interface with the p51 
subunit that is independent of the binding site near the NNRTIBP.   
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1.4.3 Summary 
 
 
Progress in RT RNHI discovery has occurred since the discovery of the natural product 
illimaquinone as an HIV-1 RNHI, where illimaquinone has been indicated to bind near residue 
C280 of the p66 subunit (63).  Since the identification of illimaquinone as an RNHI, a cascade of 
natural products (8, 39, 45, 62, 63, 65, 67, 93, 94)  and synthesized small molecules (3, 5, 6, 7, 
10, 15, 17, 24, 29, 32, 35, 40, 43, 44, 55, 56, 57, 68, 83, 90, 97, 99, 100, 102) as HIV-1 reverse 
transcriptase associated ribonuclease H inhibitors has pursued. 
 Current progress in RT RNHI discovery has been mainly focused on active site metal 
chelating small molecules, including naphthalenesulfonic acids (68), CPHM (17, 32), N-
hydroxymides (40, 57), DKAs (83, 97), N-hydroxyisoquinolines (6, 7), NACME (29, 102), 
tropolones (5, 10, 44), pyrimidinol carboxylic acids (56), and N-hydroxy naphthyridinones (90, 
100).  Only three of these classes, tropolones (44), pyrimidinol carboxylic acids (56), N-hydroxy 
naphthyridinones (90) have been confirmed to bind within the RNH active site by metal 
chelation with co-crystallized X-ray crystal structures of full length RT.  In addition, only a few 
of the proposed active site metal chelating small molecule RNHIs,  including DKAs (97) and 
hydroxyisoquinolines (6), along with confirmed active site metal chelating RNHI from the N-
hydroxy naphthyridinones class (90) have displayed antiviral activity against HIV-1 but none of 
them have been confirmed to work at the level of  HIV-1 reverse transcription during in vivo 
studies.  A few other classes of RNHIs, that are not active site metal chelating inhibitors have 
also been discussed within the literature, including vinylogous ureas (15, 99), alizarines (24, 55), 
and N-acylhydrazones (3, 9, 35, 43, 84).  Vinylogous ureas have been proposed to bind at the 
interface of the RNH domain and p51 subunit and cause heterodimer dissociation (15), though 
no structural studies have been shown to confirm the proposed binding site.  In addition, the 
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vinylogous ureas do have HIV-1 antiviral activity (15), but it has never been proven that their 
antiviral activity works at the level of HIV-1 reverse transcription.  Alizarines class of RNHIs 
have been suggested to bind within the NNRTIBP (24) but no structural studies have been 
published to prove binding within this site, while this class has no HIV-1 antiviral activity.  The 
N-acylhydrazone class of RNHIs was the first class identified as an RNHI with antiviral activity 
and is the only class to date to confirm antiviral activity works at the level of HIV-1 reverse 
transcription (9).  Furthermore, the N-acylhydrazone RNHI class has also been demonstrated by 
structural studies to bind two spatially distant locations, near the NNRTIBP (43) and within the 
interface between the RNH domain and p51 subunit (35).  Though some progress with HIV-1 RT 
RNHI discovery has been made through the past eleven years, there is still a necessity to 
discovery new RNHIs that work independent of active site metal chelation and can be developed 
as specific inhibitors of HIV-1 RT-RNH activity, that are least likely to produce potentially fatal 
off-target affects within the host. 
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1.5 RATIONALE AND STATEMENT OF HYPOTHESIS 
 
 
 Approximately 33 million people worldwide are infected with HIV-1 (98).  The U.S. 
Food and Drug Administration have approved 26 anti-HIV-1 drugs, which predominantly target 
the activities of protease and the polymerase activity of reverse transcriptase (74).  These current 
antivirals are plagued by the development of drug resistance and even though current 
combination therapies have been successful with slowing down the rate of viral mutation, drug 
resistance remains a serious issue.  There is a necessity for novel antivirals of HIV-1 to 
counteract the emergent resistant virus strains.  One plausible target is the ribonuclease H 
activity of HIV-1 reverse transcriptase.   
 There has been some progress with HIV-1 RT RNHI discovery over the past eleven 
years, since the identification of illimaquinone as an RNHI (62).  The area of RNHI discovery 
has been predominantly focused on active site metal chelating small molecules, including small 
molecules that have only been suggested as RNH active site inhibitors (6, 17, 29, 40, 57, 68, 83, 
97, 102) and small molecules that have been confirmed as active site RNHIs (10, 44, 56, 90, 100) 
through biophysical structural studies.  A few of the active site RNHIs have antiviral activity 
against HIV-1 (6, 90, 97) but none of them have been shown to directly target and inhibit the 
activity of reverse transcriptase during in vivo HIV-1 replication.  Furthermore, inhibition at the 
level of metal chelation has a potential for off-target inhibitory affects, which could be 
detrimental to the host, suggesting that metal chelating RNHIs may not be a favorable direction 
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for HIV-1 RT RNHI discovery and for this reason it certainly should not be the only avenue for 
RNHI discovery. 
 Only one class of RNHIs, N-acylhydrazones has been shown to have antiviral activity 
against HIV-1 at the level of directly inhibiting the activity of RT (9).  N-acylhydrazones RT-
RNH inhibition is not the result of active site binding and metal chelation, but rather through an 
unknown inhibitory mechanism that involves binding two spatially distinct sites within the RNH 
and polymerase domains of RT (35, 43). The ability of the N-acylhydrazones to inhibit RT-RNH 
activity independent of metal chelation makes small molecules with the hydrazone functionality 
promising leads for future RNHI discovery, therefore our laboratory hypothesizes that small 
molecules with the hydrazone or hydrazine functionality will be a highly active class of HIV-1 
RT RNHIs that can inhibit RT-RNH activity independent of active site metal chelation. 
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CHAPTER 2: IDENTIFICATION AND CHARACTERIZATION OF THE FLUOREN-9-
YILDENE HYDRAZINE PHARMACOPHORE 
 
 
 
 
2.1 ABSTRACT 
 
  
 
Screening a library of 5,292 hydrazone/hydrazine compounds for inhibition of HIV-1 RT-RNH 
activity resulted in the identification of the fluoren-9-yildene hydrazine pharmacophore as highly 
active inhibitors.  The initial 33 compounds library was expanded to an additional 118 
compounds with the fluoren-9-yildene functionality.  This focused library gave confirmed hit 
rate of 55% (65 compounds), for inhibitors of RT-RNH activity.  The fluoren-9-yildene 
hydrazine compounds turned out to be mainly monofunctional for RNH activity, since only 21% 
(25 compounds) of the compounds inhibited RT-polymerase activity.  The two most potent 
RNHIs were compounds 15 and 25, which inhibited wild type RT-RNH activity with IC50 values 
of 0.34 ± 0.07 M and 0.4 ± 0.03 M, respectively.  Similar inhibition was observed with two 
clinically relevant NNRTI resistant mutants, Y181C and K103N/ L100V.  Biochemical studies 
showed that these compounds preferentially inhibited non-directed and DNA 3'-end directed 
RNH cleavages.  Most of the compounds that were able to inhibit RT-RNH activity were also 
able to inhibit with a greater potency the RNH activity of the p15-EC RT RNH domain fragment, 
including compounds 15 and 25 having RNH IC50 values of 0.43 ± 0.04 M and 0.032 ± 0.004 
M, respectably.  Both compounds had antiviral activity against HIV-1 with EC50 values of 10 ± 
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3 M and 1.4 ± 0.6 M for compounds 15 and 25, respectively.  Order of addition experiments 
showed that potent inhibition required pre-incubation of the enzyme with the inhibitor; inhibitory 
potency substantially decreased if the RNA/DNA substrate was present prior to inhibitor 
addition.  Furthermore, inhibition was competitive with respect to the RNA/DNA substrate, 
suggesting an active site binding mode.  
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2.2 INTRODUCTION 
 
 
Previous research within our laboratory (3, 9, 35, 43, 84) and other groups (17, 32, 83) have 
identified several hydrazone inhibitors of HIV-1 RT-RNH activity, suggesting that small 
molecules with the hydrazone functionality could provided great leads for new RNHI discovery.  
Therefore, in an attempt to investigate this promising observation a small commercial library of 
5,296 hydrazone/hydrazine compounds were evaluated for HIV-1 RT RNH inhibition.  The 
library screening yielded 1,141 confirmed hits (≤ 50 % inhibition at the 10 µM screening 
concentration) with a hit rate of 22 %, indicating hydrazone/hydrazine small molecules as an 
important class of RNHIs.  A variety of different hydrazone pharmacophore classes were 
identified among the actives, including the fluorene-9-yildene hydrazine.  The complete details 
of the screening exercise will be provided in the subsequent pages.  
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2.3 MATERIALS AND METHODS 
 
 
 
2.3.1   Reagents 
 
 
A library of 5,296 compounds with the hydrazone/hydrazine functionality was obtained from 
Life Chemicals Inc (Burlington, ON, Canada).  An additional 96 fluoren-9-yildene hydrazine 
compounds were obtained from Enamine Ltd. (Kiev, Ukraine).  The expanded library contained 
118 compounds with the fluoren-9-yildene hydrazine functionality, a complete list of all the 
compound evaluated as inhibitors of RT-RNH activity can be found within appendix A: 
Supplementary Table 1.  The RNA and DNA oligonucleotides for the RNH high-throughput 
enzyme assay (HTS-1, HTS-2 and HTS-3) and dual labeled gel based RNH assay (Duplex 2 and 
Duplex4) were obtained from TriLink Biotechnologies Inc. (San Diego, CA), in which 
RNA/DNA duplexes were annealed in a 1:1 ratios.  The [3H]-TTP was obtained from Perkin-
Elmer (Waltham, Ma) and template/primer (poly(rA)-oligo(dT)16) was obtained from Midland 
Certified Reagents (Midland, Tx) for the RT polymerase enzyme assay. The 4-MUG (4-
methylumbelliferyl-β-D-galactopyranoside), a β-galactosidase fluorescent substrate was obtained 
from Sigma-Aldrich (St. Louis, MO).  P4R5 HeLa fibroblast cells were a generous gift from Dr. 
John Mellors (University of Pittsburgh) and originally obtained from Dr. Ned Landau (the Salk 
Institute for Biological Studies, La Jolla, CA).  All reagents used for all biochemical and 
virological experiments were of the highest grade possible.  
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2.3.2  Protein Expression and Purification 
 
 
 
 
2.3.2.1  Expression and Purification of  HIV-1 RT 
 
 
Plasmid p6HRT, encoding for wild-type p66/p51 heterodimeric HIV-1 RT  was a gift from Dr. 
S. Le Grice, NCI-Fredrick, Frederick, MD, USA (60), where expression and purification of was 
essentially carried out as previously described (27).  NNRTI resistant mutant, Y181C and 
K103N/ L100V were created using site directed mutagenesis.  
 
 
 
 
2.3.2.2  Expression and Purification of the p15-EC RT RNH Domain Fragment  
 
 
 Plasmid pCSR231 encoding wild-type HIV-1 p15-EC RT RNH domain fragment 
containing an alpha helical substrate-binding loop derived from E. coli RNase HI  was a 
generous gift from Dr. Daria Hazuda (Merck, West Point, PA, USA (54, 83, 89).  The protein 
was over expressed in transformed E. coli cells, in which purification was carried out as 
described later.  
 
 
2.3.3  RT Polymerase Enzyme Assay 
 
 
 Reverse transcriptase RNA-dependent DNA polymerase activity was measured as 
previously described (9),  briefly a fixed timed assay of 20 minutes at 37˚C was carried out with 
a reaction mixture (50l total volume) of 50 mM Tris-HCl (8.0 pH), 60 mM KCl, 10 mM MgCl2, 
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8.6 nM wild type RT, 40 nM of template/primer (poly(rA)-oligo(dT)16), and 11.2 M of 
[3H]TTP substrate.  Inhibitors were dissolved in 100% DMSO, while aliquots of inhibitors added 
to the reaction mixture were added such that the final DMSO concentrations were no more than 
1% with inhibitor concentrations ranging from 0.2-25 M with at least six concentrations.  
Reactions were quenched by 200 l ice cold 10 % TCA containing 20 mM sodium 
pyrophosphate and filtered using a 1.2 M glass fiber filter 96-well plates (Millipore) followed 
by sequentially wash with 10% TCA and ethanol.  The extent of radionucleotide incorporation 
was determined by liquid scintillation spectrometry, using a 1450 Microbeta scintillation counter 
(Perkin Elmer). The IC50 values were determined as described below with the RNH FRET high-
throughput enzyme assay using SigmaPlot software (version 11.0, Systat Software Inc., San 
Jose, CA).   
 
 
 
2.3.4   High-Throughput Screening Substrates for RNH activity 
 
 
 
 
Table 2: Nucleic Acid Substrates for RNH FRET High-Throughput Enzyme Assay 
 
 
Substrate Sequence  Comments 
HTS-1 
        
        5’-gaucugagccugggagcu -3’-fluorescein RNA 
        3’-CTAGACTCGGACCCTCGA -5’-Dabcyl DNA 
 
Non-directed 
substrate 
HTS-2 
 
  5’–cugguuagaccagaucugagccugggagcu–3’-fluorescein RNA 
                         3’-GGTCTAGACTCGGACCCTCGA–5’-Dabcyl DNA 
 
DNA 3’-end 
directed substrate 
HTS-3 
             
         5’–accagaucugagccugggagcu–3-fluorescein RNA 
3’-GACCAATCTGGTCTAGACTCGGACCCTCGA–5’-Dabcyl DNA 
 
RNA 5’-end 
directed substrate 
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Three high-throughput substrates (HTS) (Table 2) were used in order to probe for specific modes 
of RT RNH cleavages (discussed in Chapter 1, section 1.3.3) in a previously described rapid 
fluorescence based assay (26).  A non-directed cleavage substrate (HTS-1) was designed to 
probe for inhibition of non-directed RNH cleavages, since the RNA/DNA hybrid is 3' and 5' 
blunt ended.  The DNA 3'-end directed cleavage substrate (HTS-2) was designed to probe for 
inhibition of polymerase dependent RNH cleavages, since the 3'-end of the DNA strand of the 
RNA/DNA hydrid is recessed.  The last substrate, HTS-3 was designed as RNA 5'-end directed 
cleavage substrate in order to probe for inhibition of polymerase independent cleavages, since 
the 5'-end of the DNA strand of the RNA/DNA hybrid is recessed. 
 
 
 
2.3.5   RNH FRET High-Throughput Enzyme Assay 
 
RNH activity of the RT heterodimer (wild type and NNRTI mutants, Y181C or K103N/L100V) 
and wild type p15-EC RT RNH domain fragment were determined using a previously described 
rapid fluorescence based assay (26).  RT RNH high-throughput enzyme studies were conducted 
under both a fixed time point and kinetic time point, in which the fluorescence was monitored in 
real time.  
  The fixed time point assay was carried out using the Precision 2000 automatic pipetting 
system from BioTek Instruments, Inc. (Winooski, VT) at room temperature to carry out and 
quench the reaction after a 10 minute reaction time with 0.1 M EDTA (8.0 pH).  The automatic 
pipetting system was not used for the kinetic studies.  RT experimental reactions contained      
8.5 nM enzyme to 250 nM HTS-1, HTS-2 or HTS-3 RNA/DNA substrate (50, 150 and 350 nM 
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for kinetic studies) in a buffer of 50 mM Tris-HCl (8.0 pH), 60 mM KCl, 1 mM MgCl2 and 1% 
DMSO.  The inhibitors were pre-incubated with the enzyme at room temperature for ~5 minutes, 
unless otherwise mentioned.  Inhibitor concentrations ranged from 0.2-25 M with at least six 
concentrations, in which the fluorescence intensity was quantified using BioTek Synergy4 
microplate reader (BioTek Instruments, Inc., Winoosk, VT) at an excitation wavelength of 485 
nm and an emission wavelength of 528 nm.  The kinetic assay had a lag time of ~45 seconds, in 
which a time point was obtained every 60 seconds up to 15 minutes.  The rate of RNH cleavages 
was obtained by fitting the linear portion (45-360 seconds) of the fluorescent signal with a non-
linear regression equation (y = mx + b) using SigmaPolot software (version 11.0, Systat 
Software Inc., San Jose, CA) for each inhibitor and substrate concentration.  A dixon plot was 
used to determine the type of RNH inhibition and the inhibition constant (KI) was obtained with 
the equation KI = (IC50) / (1 + S/Km), being that S is the substrate concentration (250 nM) and Km 
is the Michaelis-Menton constant (Km = 54 nM with 8.5 nM RT and 50-350 nM HTS-1, under 
the same experimental conditions).  The IC50 value used was from previously determined values 
during the fixed time point reactions, being 0.4 ± 0.03 M for compound 25.  
 The p15-EC RT RNH domain fragment reaction mixture contained 8 nM enzyme to    
500 nM HTS-1 substrate in a buffer of 50 mM Tris-HCl (8.0 pH), 5 mM KCl and 2 mM MnCl2 
at room temperature (using the automatic pipetting system).  The reactions were carried out 
identical to the rections with RT heterodimer including pre-incubation and reaction times at 
room temperature, except reactions were initiated upon addition of substrate in the presence of 
Mn+2 instead of Mg+2.  Inhibitor concentrations ranged from 0.2-25 M with at least six 
concentrations, unless the IC50 value was determined to be less than 0.2 M in which new dose 
responses range of 6.3-800 nM with at least six concentrations were used. 
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 IC50 values were determined by fitting the dose response data to a non-linear regression 
equation y = (a*b)/(b+x), with the SigmaPlot software (version 11.0, Systat Software Inc., San 
Jose, CA).  x is defined as the inhibitor concentration,  y is the relative fluorescence units (RFU) 
resulting from RNH cleavage, a is defined as the maximum RFU value and b is defined as the 
IC50 value in which b= x*50(x,y).  All experiments were done in at least duplicate in which each 
experiment was repeated at least twice, the average and standard deviations were calculate from 
the each individual experiments that was done in at least duplicate.  
 
 
2.3.6   Gel Based Dual Labeled RNH Assay 
 
 
Table 3: Nucleic Acid Substrates for the Gel Based Dual Labeled RNH Assay 
 
 
Substrate Sequence 
RNA 5’-end 
directed substrate 
(Duplex 2) 
            RNA 5'-Cy3-ccacugcuagagauuuucgacac-Cy5 
DNA 3'-GTCCAGGACAAGCCCGCGGTGACGATCTCTAAAAGCTGTGACTG-5' 
 
DNA 3’-end 
directed substrate 
(Duplex 4) 
 
RNA 5'-Cy3-gucaguguggaaaaucucuagcaguggcgcccgaacagggaccugaccag-Cy5 
                                DNA 3'-GGCTTGTCCCTGGACTGGTC-5' 
 
  
 
Reactions were carried out at room temperature for ~10 minutes with 50 nM RNA/DNA 
Substrate, 10 nM wild type RT, 1 mM MgCl2, 50 mM Tris-HCl (8.0 pH), 50 mM KCl and 0.5 
mM EDTA (8.0 pH) and 1% DMSO.  Two different substrates (Table 3) were used to probe for 
inhibition of specific modes of RT-RNH cleavages, including RNA 5'-end directed cleavages 
(duplex 2, analogous to HTS-3) and DNA 3'-end directed cleavages (duplex 4, analogous to 
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HTS-2), enabling probing of polymerase independent and dependent cleavages, respectively.  All 
reactions were carried out in presence of RNase free water with 0.5 mM EDTA (8.0 pH) in order 
to prevent any non-specific cleavages prior to the initiation of the reaction.  Inhibitor 
concentrations were at 5 M for compounds 6, 15 and 25.  Reactions were quenched with a 1:1 
mixture of 1% formamide and 10 mM EDTA (pH 8.0) at time point of 0, 0.5, 1, 1.5, 2,  2.5, 5 
and 10 minutes.  A 12% PAGE SDS gel with 7 M urea was used to separate the cleavage 
products.  The Typhoon 9400 PhosphorImager, (version 3.0.0.0, Amersham Bioscience, 
Sunnydale, CA) with the  Fluorochrome Separation application, (version 1.0.0.1) and 
ImageQuant application (version 1.0.01)  was used to obtain an image of the gels, separate the 
cy3 and cy5 fluorescent signals and quantify the bands at 100 microns.   
 
 
2.3.7   RNH Order of Addition Studies 
 
Order of addition studies were carried out with both the kinetic RNH FRET high-throughput 
enzyme assay and the gel based dual labeled RNH assay.  Four different enzyme pre-incubation 
conditions were evaluated, including enzyme-inhibitor, enzyme-substrate, enzyme-substrate-
inhibitor and without enzyme pre-incubation.  Enzyme-inhibitor pre-incubation (EI) studies were 
carried out as described under section 2.3.5, briefly the inhibitor was pre-incubated with the 
enzyme for ~5 minutes at room temperature and initiated by addition with a substrate-metal 
mixture.  Enzyme-substrate pre-incubation (ES) experiments were carried out for ~5 minutes at 
room temperature and the reaction was initiated by the addition of the inhibitor-metal reaction 
mixture.  During the enzyme-substrate-inhibitor pre-incubation (ESI) experiments, the enzyme 
was added to a mixture of inhibitor with the substrate and allowed to pre-incubate for ~5 minutes 
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at room temperature, in which the reaction was initiated with the MgCl2 mixture.  Experiments 
without enzyme pre-incubation (E) were carried out by initiating the reaction by adding the 
enzyme to a mixture of the inhibitor, substrate and Mg+2.  Experimental conditions for both the 
kinetic RNH FRET high-throughput enzyme assay and the gel based dual labeled RNH assay 
were carried out identical (expect noted in the preceding), as stated in the above sections 2.3.6 
and 2.3.7, respectively.  The kinetic RNH FRET high-throughput enzyme assay was carried for a 
total of 10 minutes, in which the rates of RNH cleavages was obtained by fitting the linear 
portion of the fluorescence data from 47-347 seconds.  Inhibitor concentrations for wild type RT 
with HTS-1 reaction ranged from 0.05-25 M, while with the p15-EC RT RNH domain 
fragment with HTS-1 ranged from 0.002-5 M.  The gel based dual labeled RNH assay was 
carried out for 1 minute at 26°C, in order to prevent additional RNH cleavages beyond the 
primary cut.  
 
 
2.3.8 HIV-1 Antiviral Studies 
 
 
 
Inhibitors from the fluorene-9-yidene hydrazine library were accessed for HIV-1 antiviral 
activity with the P4R5 cell line through a single-cycle viral replication fluorescence-based 
microplate β-galactosidase detection assay (5 or 25 ng of viral p24 per 5 x 103 cells per well).  
P4R5 HeLa fibroblast cells, express endogenous CXCR4, along with stably transfected CD4, 
CCR5 and a β-galactosidase reporter gene under the control of an HIV LTR promoter (69).  The 
cell line was maintained in DMEM/10% FBS and supplemented with 0.5 g/ml puromycin.  An 
infectious molecular clone of IIIB (HxB2) strain of HIV-1 was encoded within a pSVC21-BH10 
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plasmid, which carries an SV40 origin of replication for expression in 293T and COS-7 cells 
(26).  Calcium phosphate co-precipitation transfection with 293T cells was used to prepare the 
HIV-1 virus particles, then 60 hours post-transfection the virus containing culture supernatant 
was collected and clarified by centrifugation (3000x g, 1 hour at 4°C).  Viral quantification was 
done through quantification of the levels of HIV-1 p24 antigen, in which the virus particle 
infectivity was determined by using normalized quantities of HIV-1 p24 antigen contents with 
P4R5 cells as targets.  HIV-1 virus particle stocks were then aliquoted and stored at -80°C until 
use. 
 Inhibitors were pre-incubated with  the P4R5 cells 24 hours prior to HIV-1 addition with 
inhibitor concentration ranging from 0.5-25 M, in which 48 hours post-infection virus-
containing culture supernatant was removed.  The cells were lysed in 100L lysis buffer of 60 
mM Na2HPO4, 40 mM NaH2PO4 (pH 7.2), 1 mM MgSO4, 100 mM mercaptoethanol, 2% triton 
[v/v] X-100 for 1 hour at 37°C, in which reactions were initiated by a final concentration of 0.5 
mM 4-MUG (50L) and incubated for 1 hour at 37°C.  Reactions were quenched with 150 L of 
0.2 mM Na2CO3 (11.2 pH).  BioTek synergy multi-mode microplate reader (BioTek Instruments, 
Inc., Winoosk, VT) was used to quantify the fluorescence intensity using an excitation 
wavelength of 355nm and an emission wavelength of 480nm.   
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2.4 RESULTS 
 
 
 
 
2.4.1   Initial Identification and Expansion of the Fluoren-9-yildene Hydrazine Library 
 
 
 
 
 
 
Figure 19.  Fluoren-9-ylidene Hydrazine Pharmacophore 
 
 
 
The fluoren-9-yildene hydrazine pharmacophore (Figure 19) was identified from a screening of 
a biased library of 5,296 compounds using a high-throughput FRET RNH enzyme assay (26).  
This screening identified 338 compounds with an 80% or greater inhibitors of HIV-1 wild type 
RT-RNH activity at 10 M.  The fluorene-9-yildene hydrazine pharmacophore was identified 
within this highly active subset of compounds.  The potency and novelty of the fluorene-9-
yildene hydrazine inhibitor class warranted more detailed study.  
 Of the initial 33 fluoren-9-yildene hydrazine compounds from the larger library, 70% 
inhibited RT-RNH activity with an IC50 range of 340 ± 0.7 nM to 13 ± 0.1 M, where only 10 of 
the compounds had no RT-RNH inhibition up to 25 M.  In addition, it was also identified that 
these compounds inhibited the  p15-EC RT RNH domain fragment with nanomolar IC50 range, 
indicating this pharmacophore class as remarkably active RNHIs that directly interact with the 
RNH domain, since they were also able to inhibit the RNH domain.  From these promising 
N
HN
R1
R3 R3
R2
R2
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results, the fluorene-9-yildene hydrazine library with an additional 96 compounds, creating a 
library was expanded with a total of 118 discrete fluorene-9-yildene hydrazine analogues (there 
were duplicate compounds from the two sources)  
 
 
 
2.4.2   Characterization of the Expanded Fluoren-9-yildene Hydrazine Library for RNH  
Inhibition with HIV-1 Wile Type RT 
 
 
 
 
 
Figure 20.  Correlation Between RT-RNH and Pol Inhibition.   
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Table 4:  Most Active RNHIs from Each Subgroup 
 
              
  
 
 
 
 
 
 
 
  
 
 
 
 
Biochemical experiments were carried out using the fixed time point high-throughput FRET 
RNH enzyme assay to evaluate for HIV-1 RT RNH inhibition.  Screening of the expanded 
fluorene-9-yildene hydrazine library for inhibitors of HIV-1 reverse transcriptase ribonuclease H  
activity, resulted in a hit rate of 55%  (65 compounds) with  IC50 values < 10 M.  The library of 
fluorene-9-yildene hydrazine compounds were fundamentally monofunctional for RT-RNH 
inhibition, since only 25 (21%) of the compounds had IC50 values < 10 M with inhibiting RT-
polymerase activity.  In fact the majority of the compounds, 78 (66%) were unable to inhibit RT 
RDDP activity at maximum tested concentration.  Figure 20, shows that the fluorene-9-yildene 
hydrazine compounds overall are better inhibitors of RT-RNH activity versus polymerase 
Subgroup Compound Structure RT-RNH IC50 (M) 
RT-Pol 
IC50 (M) 
A 
 
 
1 
 
  
1.1 ± 0.2 5.6 ± 0.6 
B 
 
 
15 
 
 
0.34 ± 0.07 0.62 ± 0.06 
C 
 
 
25 
 
 
 
0.4 ± 0.03 
 
1.5 ± 0.1 
D 
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activity, in which 58% of the RNH hit compounds had IC50 values within the 0.34-5 M 
concentration range, while the polymerase IC50 values are more spread out with 90% of the hit 
compounds ranging from 0.62-15 M concentration, excluding a few outliers.  All of the 
compound's HIV-1 RT-RNH and polymerase IC50 values and corresponding structures for the 
full fluorene-9-yildene hydrazine library can be found in appendix A: Supplementary Table 1.  
The most potent HIV-1 RT RNHIs were compounds 15 and 25 (Table 4), with an IC50 values of 
0.34 ± 0.07 M and 0.4 ± 0.03 M, respectively.  In addition, both compounds also inhibited 
HIV-1 RT-polymerase activity with an IC50 of 0.62 ± 0.06 M for compound 15 and 1.5 ± 0.1 
M for compound 25.  
 
 
 
 
2.4.3   Four Structural Subgroups of the Fluoren-9-yildene Hydrazine Library 
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Figure 21.  RT-RNH and polymerase Inhibition per Subgroup.  A) RT-RNH inhibition per  
subgroup and B) RT-polymerase inhibition per subgroup. 
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Table 5:  Subgroups of the Fluoren-9-ylidene Hydrazine Library 
 
 
 Subgroup # RNHIs 
RT- RNH Inhibition RT-Pol Inhibition 
# Actives 
(< 10 M IC50) 
IC50 
Range 
(M) 
# Actives 
(< 10 M IC50) 
IC50 
Range 
(M) 
A 
 
2-(9H-fluoren-9-ylidene) 
hydrazinecarboxamids 
 
14 8 (57%) 1.1-9 4 (29%) 5.6-8.1 
B 
 
2-(9H-fluoren-9-ylidene) 
hydrazinecarbothioamide 
 
10 5 (50%) 0.34-5.6 2 (20%) 0.62-2.3 
C 
 
1-(9H-fluoren-9-
ylidene)-2-
phenylhydrazine 
 
33 26 (79%) 0.4-7.7 13 (39%) 0.7-8.6 
D 
 
N’-(9H-fluoren-9-
ylidene) 
benzohydraside 
 
38 17 (45%) 1.34-9 3 (8%) 1.0-3.6 
E 
 
Other  
 
23 9 (39%) 0.5-6 3 (13%) 1.7-9.4 
         
 
 
Analysis of the fluoren-9-ylidene hydrazine library as RNH inhibitors identified four primary 
subgroups based on the functional group directly attached to the hydrazine (R1, Fig 20), along 
with an additional 23 compounds classified as other.  The characteristics of each subgroup for 
HIV-1 RT-RNH and polymerase inhibition are found in Table 5.   
 The first subgroup (A), 2-(9H-fluoren-9-ylidene)hydrazinecarboxamids has a 
carboxamide substituent at R1.  This subgroup consists of 14 compounds and is the second to 
smallest subgroup.  Subgroup A produced 8 (57%) compounds that inhibit RT-RNH activity 
with IC50 values ranging from 1.1-9 M, making this subgroup the third most active subgroup as 
a fluoren-9-ylidene hydrazine RNHI.  This subgroup had 4 (29%) compounds that inhibit RT-
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polymerase activity with IC50 values ranging from 5.6-8.1 M.  As seen in Figure 21A, IC50 
value for RT-RNH inhibition for this subgroup is centered around 1.1-5 M, excluding a few 
outliers. The RT-polymerase inhibition for this subgroup, as seen in Figure 21B, is centered 
around IC50 values of 5.6-10 M.  The most active compound from this subgroup (compound 1) 
had an RT-RNH IC50 of 1.1 ± 0.2 M and RT-polymerase IC50 of 5.6 ± 0.6 M (appendix A, 
Supplementary Table 1).     
 The second subgroup (B), 2-(9H-fluoren-9-ylidene)hydrazinecarbothioamide has a 
carbothioamide substituent at R1.  This subgroup consists of 10 compounds and is the smallest 
subgroup of the library.  As seen in Figure 21A, the RT-RNH inhibition is centered around 0.34-
3 M IC50 value range, while most of the compounds from this subgroup were inactive inhibitors 
against RT-polymerase activity (Figure 21B).  Of the 10 compounds, 5 (50%) inhibited RT-RNH 
activity with IC50 values ranging from 0.34-5.6 M. Furthermore, the compounds within this 
subgroup are poor inhibitors of RT-polymerase activity, in which only 2 (20%) compounds 
inhibited with an IC50 less than 10 M.  This subgroup also contains one of the most active 
fluoren-9-ylidene hydrazine RNHIs (compound 15).  Compound 15, inhibits RT-RNH activity 
with an IC50 value of 0.34 ± 0.07 M and RT-polymerase activity with an IC50 value of 0.62 ± 
0.06 M (appendix A, Supplementary Table 1).   
 The third subgroup (C), 1-(9H-fluoren-9-ylidene)-2-phenylhydrazine has a phenyl group 
substituent at R1.  Subgroup C is the second largest subgroup with 33 compounds and the most 
active subgroup as an RNHI.  Of the 33 compounds, 26 (79%) inhibited RT-RNH activity and 13 
(39%) of the compounds inhibit RT-polymerase activity (Table 5), making this subgroup the 
most bifunctional subgroup from the whole library.  The RT-RNH IC50 values centered around 
0.4-5 M IC50 values (Figure 21A), while the polymerase IC50 values were centered around 0.4-5 
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M IC50 (Figure 21B).  This subgroup also contains one of the most potent RT-RNHIs 
(compound 25) with an RT-RNH IC50 value of 0.4 ± 0.03 M and a RT-polymerase IC50 value 
of 1.5 ± 0.03 M (appendix A: Supplementary Table 1).   
 The fourth subgroup (D), N’-(9H-fluoren-9-ylidene)benzohydraside  has an N-
acylhydrazone substituent at R1. This subgroup consists of 38 compounds and is the largest 
subgroup for the fluoren-9-ylidene hydrazine library but it is the least active group as an RNHI.  
Of the 38 compounds, 17 (45%) inhibit RT-RNH activity with IC50 values of 1.34-9 M (Table 
5).  As seen in Figure 21A, the RT-RNH inhibition was spread out and not localized around a 
specific IC50 range.  This subgroup is primarily monofunctional as an RT-RNH inhibitor, since 
only 3 (8%) of the compounds inhibited RT-polymerase activity with IC50 values ranging from 
1.0-3.6 M.  Figure 21B, further shows that for the compounds that do have RT-polymerase 
inhibitory activity, with IC50 values that are spread out.  The most active compound from this 
subgroup was compound 58 with an RT-RNH IC50 of 1.3 ± 0.2 M and RT-polymerase IC50 of 
2.3 ± 0.2 M (appendix A: Supplementary Table 1).   
 The remaining 23 compounds from the fluoren-9-ylidene hydrazine library that were not 
separated into any of the other four functional subgroups were clumped into a fifth subgroup, 
referred to as "Other " (E).  Compounds within this subgroup lacked any well-defined structural 
similarities for substituents at R1. Most of the compounds within this subgroup were mainly 
monofunctional RNHIs, in which 9 (39%) of the compounds were active with IC50 values 
ranging from 0.5-6 M. The few compounds that are bifunctional as RT-RNH and polymerase 
inhibitors, are the least active compounds against RT-polymerase activity compared to the rest of 
the library, with IC50 values ranging from 1.7-9.4 M.   
 
 61 
 
2.4.4   Structural Moieties Significant for RT-RNH Inhibition  
 
 
 
Table 6.  9H-(fluoren-9-ylidene)-2-hydropranolcarboxylhydrazines Compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure activity analysis of the fluoren-9-ylidene hydrazine library based on their inhibition of 
full length RT-RNH (appendix A: Supplementary Table 1) has resulted in the identification of 
some structural moieties that enhance RT-RNH inhibition.  A phenyl group substituent at the R1 
position as with compound 25 or with a thioamide linker between the hydrazine and phenyl 
group substituent, as seen with compound 15, enhances RNH inhibition of RT RNH activity.  
Comparison of compounds 20 (11 ± 0.5 M RNH IC50) and 23 (> 25 M RNH IC50) indicates 
Compounds RT-RNH      IC50 (M) 
RT-Pol       
 IC50 (M) 
119 >25 >25 
120 >25 >25 
121 >25 >25 
122 
 >25 >25 
123 11 ± 0 >25 
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that replacement of the R1 phenyl group with a non-aromatic ring system or aliphatic chain has a 
detrimental effect on RT-RNH and polymerase inhibition, in which substitution with an aliphatic 
group completely abrogates inhibition.   
 In addition, extension of the R2 position with a sulfonamido-phenyl ring substituent 
results in the most potent inhibition of RT RNH and polymerase inhibition, as seen with 
compounds 15 and 25.  This observation is evident when comparing  two compounds, 25 and 44 
in which only compound 25 has a phenyl substituent added to the R2 sulfonamido and compound 
44 lacks the phenyl group.  Compound 25 is a more potent RT-RNHI with an IC50 of 0.4 ± 0.03 
M, while compound 44 has an approximate ten-fold decrease in RNH inhibition with a 4.4 ± 
0.3 M IC50.  Furthermore, the RT-polymerase inhibition with these two compounds has a six-
fold difference, where compound 25 has a greater RT-polymerase inhibition of 1.5 ± 0.1 M 
IC50 and compound 44 has an IC50 of 8.2 ± 0.7M.  Additional observations with compounds 31 
and 37 with aliphatic substitutions added to the R2 sulfonamido-phenyl ring results in a loss in  
RT-RNH IC50 values of 1.7 ± 0.1M and 2.4 ± 0.5M, respectively.  These structural activity 
relationship observations suggest that a bulky ring system at the R2 sulfonamido position is 
required for enhancement in RNH inhibition.  Compounds 35 and 43 with a bulky ring system 
without aromaticity, as seen with the phenyl substitution at the R2 sulfonamide position have an 
additional loss in RT-RNH inhibition with IC50 values of 2.1 ± 0.2 M and 3.7 ± 0.4  
(respectively).  These further observations suggest that it is not just a bulky ring system, which is 
necessary for enhancement in RT-RNH inhibition but also the aromatic functionality of the 
sulfonamido-phenyl ring that is necessary.  The necessity of the R2 sulfonamido-phenyl ring 
substitution is further supported by the fact that compound 15 from subgroup B, is the only 
compound from that subgroup that has the R2 sulfonamido-phenyl ring substitution and is the 
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only compound within subgroup B that has significant RT-RNH inhibition.  It is further seen that 
the ortho iodine addition to the R2 sulfonamido-phenyl ring system (compound 25) is responsible 
for the enhancement in RT-RNH inhibition versus the iodine itself; this is evident when 
comparing compounds 25 and 30 (RT-RNH IC50 of 1.6 ± 0.2 M) with either an ortho iodine or 
para chloride additions.  
During initial screening of the hydrazone/hydrazine library (5,592 compounds) where the 
fluoren-9-ylidene hydrazine pharmacophore was first identified (Figure 19, subsection 1.4.1), 
another subset of five compounds [9H-(fluoren-9-ylidene)-2-hydropranolcarboxylhydrazines] 
having a similar structure as the fluoren-9-ylidene hydrazine pharmacophore were identified, as 
seen in Table 6.  These compounds have both of the structural components of the fluoren-9-
ylidene hydrazine pharmacophore, namely the fluorene and hydrazine functional groups but have 
an additional 2-hydropranolcarboxyl linker is between the flourene and hydrazine functional 
groups.  Addition of the 2-hydropranolcarboxyl linker results in a complete loss of inhibition 
potency.  This suggests that comparison of the planar fluoren-9-ylidene hydrazone linkage to the 
tetrahedral geometry is detrimental to inhibition. 
 
 
 
2.4.5   Fluoren-9-yildene Hydrazine Library RNH Inhibition of the p15-EC RT RNH  
Domain Fragment 
 
 
Biochemical experiments were undertaken using the fixed time high-throughput FRET RNH 
enzyme assay to evaluate the fluoren-9-ylidene hydrazine library for inhibiting the RNH activity 
of p15-EC RT RNH domain fragment.  Evaluating inhibition of the p15-EC RT RNH domain 
fragment enables direct confirmation that the fluoren-9-ylidene hydrazine compounds directly 
interact with the RNH domain, since the p15-EC is a modified isolated RNH domain of HIV-1 
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RT in which an extended E. coli helix-loop was added in order to restore activity to the enzyme 
(54).  Screening of the library (118 compounds) resulted in a hit rate of 78% (99 compounds), 
having IC50 values < 10 M, as inhibitors of RNH activity (complete list of the IC50 values can 
be found under appendix A: Supplementary Table 1).  These results suggest the RT-RNH 
inhibtion of the fluoren-9-ylidene hydrazine compounds is the result of directly interacting with 
the RNH domain, in fact the compounds were more potent RNHIs with the p15-EC RT RNH 
domain fragment versus full length RT.  As seen with Figure 22A, majority of the compounds 
are able to inhibit the RNH domain fragment with 56% of the actives localized around IC50 
values of 0.018-0.8 M.  A correlation is seen with being able to inhibit the p15-EC and full 
length RT (Figure 22A), excluding a few outliers.  Of the 33 compounds within in subgroup C, 
30 (91%) of them inhibited RNH activity (Table 7), with IC50 values centered around 0.032-0.7 
M range (Figure 22B).  A similar trend is seen with compounds from subgroups A and B, in 
which 7 (70%) compounds from subgroup B  and 9 (64%)  compounds from subgroup A 
inhibited RNH activity (Table 7). Subgroup D was the least potent group for RT-RNH inhibition 
but it was the second most potent subgroup with the p15-EC RT-RNH domain fragment, in 
which 30 (79%) of the compounds inhibited RNH activity with with IC50 values ranging from 
0.018-8.2 M (Table 7).  Figure 22B, further shows that the compounds from subgroup D were 
less localized and more spread out compared to the other subgroups, in which Subgroup D 
contains the most potent p15-EC RT RNH domain fragment inhibitor (compound 58) with an 
IC50 value of 0.018 M (appendix A: Supplementary Table 1).  
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 Figure 22.  RNH Inhibition of the p15-EC RT RNH Domain Fragment.  A) RNH inhibition  
correlation with the RNH domain fragment and length RT.  B) RT-RNH inhibition 
per subgroup. 
 
 
 
Table 7:  Subgroup RNH Inhibition with the p15-EC RT RNH Domain Fragment 
 
 
 Subgroup # Compounds 
p15-EC RT RNH Domain  
Fragment Inhibiton 
# Actives 
(< 10 M IC) IC50 Range (M) 
A 
 
2-(9H-fluoren-9-ylidene) 
hydrazinecarboxamids 
 
14 9 (64%) 0.23-3.5 
B 
 
2-(9H-fluoren-9-ylidene) 
hydrazinecarbothioamide 
 
10 7 (70%) 0.05-3.8 
C 
 
1-(9H-fluoren-9-ylidene)-
2-phenylhydrazine 
 
33 30 (91%) 0.032-4.2 
D 
 
N’-(9H-fluoren-9-ylidene) 
benzohydraside 
 
38 30 (79%) 0.018-8.2 
E 
 
Other  23 16 (70%) 0.11-5.3 
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2.4.6   Fluoren-9-ylidene Hydrazine Compounds Preferentially Inhibit Non-directed and  
DNA 3'-end Directed  Modes of RNH Cleavages 
 
 
 
 
Table  8.  Fluoren-9-ylidene Hydrazine Inhibition with Different HTS Substrates 
 
 
 
 
 
 
 
                 
 
 
Figure 23.  Correlation Between RT-RNH Inhibition with Non-directed and DNA 3'-end  
Directed Cleavage Substrates 
 
 
 
The fluoren-9-ylidene hydrazine compounds were shown to be highly active inhibitors of RNH 
activity with full length RT, while also directly inhibiting the p15-EC RNH domain fragment, 
therefore the compounds were further evaluate for inhibiting specific modes of RT RNH 
cleavages (discussed within Chapter 1, under subsection 1.3.3).  The fixed time point high-
throughput FRET RNH enzyme assay was used to evaluate inhibition of specific modes of RT 
RNH cleavages using all three RNA/DNA substrates, HTS-1, HTS-2 and HTS-3 (Table 2). 
Compound RT-RNH HTS-1 IC50 (M) 
RT-RNH HTS-2 
IC50 (M) 
RT-RNH HTS-3 
IC50 (M) 
15 0.34 ± 0.07 0.47 ± 0.03 1.3 ± 0.3 
25 0.4 ± 0.03 0.6 ± 0.1 1.9 ± 0.2 
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  The complete fluoren-9-ylidene hydrazine library was evaluated as RT-RNH inhibition 
with the non-directed (HTS-1) and DNA 3'-end directed (HTS-2) cleavage substrates.  Screening 
of the library for non-directed RNH cleavages with HTS-1 resulted in a hit rate of 55% (IC50 
values < 10 M), while evaluation with HTS-2 resulted in a similar hit rate of 52%.  A 
correlation was seen with the RT-RNH IC50 values with HTS-1 and HTS-2 substrates (Figure 
23), such that individual IC50 values were insignificant for each other for the majority of the 
compounds, excluding a few outliers.  The lack of preference for non-directed and DNA 3'-end 
directed RNH cleavages can further be seen with compounds 15 and 25 (Table 8), where 
compound 15 had an IC50 of 0.34 ± 0.07 M (HTS-1) and 0.47 ± 0.03 M (HTS-2), while 
compound 25 had an IC50 of 0.4 ± 0.03 M (HTS-1) and 0.6 ± 0.1 M (HTS-2).  Neither 
compound 15 or 25 showed a preference for inhibiting non-directed and DNA 3'-end directed 
RNH cleavages, but both compounds were less potent with inhibiting RNA 5'-end directed RNH 
cleavages substrate (HTS-3), as seen in Table 8.  The compounds had an approximate three-fold 
decrease in inhibitory potency with the RNA 5'-end directed cleavages substrate (HTS-3) 
compared to HTS-1 and HTS-2 cleavages, having IC50 values of 1.3 ± 0.3 M and 1.9 ± 0.2 M 
with HTS-3 substrate, respectively.  These results indicate that the two most potent fluoren-9-
ylidene hydrazine RT-RNH inhibitors, compounds 15 and 25 preferentially inhibit non-directed 
and DNA 3'-end directed cleavages over RNA 5'-end directed cleavages with the high-
throughput FRET RNH enzyme assay. 
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Figure 24.  RT-RNH Inhibition of DNA 3'-end and RNA 5'-end directed RNH cleavages 
A) RT-RNH inhibition of RNA 5'-end directed RNH cleavages (Duplex 2) and 
B) RT-RNH inhibition of DNA 3'-end directed RNH cleavages (Duplex 4).  C) 
Quantification of RNA 5'-end directed RT-RNH cleavages (Duplex 2) and D) 
Quantification of DNA 3'-end directed RT-RNH cleavages (Duplex 4). 
 
 
 
A gel based dual labeled RNH assay was also used to evaluate preferential inhibition of either 
DNA 3'-end or RNA 5'-end directed cleavages with two different substrates, using a DNA 3'-end 
directed (duplex 4, analogous to HTS-2) or an RNA 5'-end directed (duplex 2, analogous to 
HTS-3) cleavages substrate, as seen in Table 3. The gel based assay was used in conjunction to 
the high-throughput RNH FRET enzyme assay because it can provide information on the 
B A 
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location of RNH cleavage and the RNA/DNA substrates are longer and perhaps more relevant to 
the viral RNA/DNA substrate compared to the high-throughput substrates (HTS).  The most 
potent compounds from subgroups A (6), B (15) and C (25) were evaluated at 5 M 
concentrations.  All three compounds were able to inhibit RNA 5'-end directed cleavages (duplex 
2) to various extents of inhibition potency (compounds 6 > 25 > 15), whereas all three 
compounds were able to completely inhibit the DNA 3'-end directed cleavages (duplex 4) 
(Figure 24).   
 
 
 
2.4.7   Fluoren-9-ylidene Hydrazine Type of RNH Inhibition is Competitive with Respect to  
the RNA/DNA Substrate 
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Figure 25.  Dixon Plot of Compound 25 with Non-directed Cleavage Substrate 
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Kinetic high-throughput FRET RNH enzyme studies with compound 25 and the non-directed 
RT-RNH cleavage substrate (HTS-1) resulted in competitive RT-RNH inhibition with respect to 
the RNA/DNA substrate with a KI of 0.14 M, as seen in Figure 25 with the Dixon-plot 
analysisiii.  Competitive inhibition is evident, since linear fitting of the inhibition dose response 
data at three different substrate concentrations (50, 150 and 350 nM) cross and intersect beyond 
the y-intercept.  Competitive inhibition with the substrate, suggests that the inhibitor competes 
with the substrate for binding within the RNH active site.   
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Figure 26.  Order of Addition Influence on RNH Inhibition with Full Length RT and the  
p15-EC RT RNH Domain Fragment usimg the High-throughput FRET RNH 
Enzyme Assay.  A) RT-RNH inhibition of non-directed RNH cleavages (HTS-1) 
with RT and B) RT-RNH inhibition of non-directed directed RNH cleavages 
(HTS-1) with RNH domain fragment (p15-EC).  Enzyme-inhibitor pre-incubation 
is denoted by EI, enzyme-substrate pre-incubation (binary complex) denoted by 
ES, enzyme-substrate-inhibitor pre-incubation denoted by ESI and no enzyme pre-
incubation denoted by E. 
 
 
 
Additional order of addition studies were carried out to see if the inhibitors would be able to 
compete with the substrate and inhibit the binary complex form (RT-substrate), since previous 
                                                 
iii Kinetic studies may not have been carried out under equliibrium conditions 
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kinetic studies discussed above showed compound 25 is competitive with respect to the 
RNA/DNA substrate.  A kinetic high-throughput FRET RNH enzyme assay with full length RT 
and the p15-EC RT RNH domain fragment using the non-directed cleavage substrate (HTS-1) 
was carried out to evaluate RNH inhibition with four different reaction enzyme pre-incubation 
conditions.  The first condition evaluated was pre-incubation of the inhibitor with the enzyme 
(denoted EI), prior to addition of the substrate and metal ions, allowing us to probe if the 
inhibitor could prevent essential enzyme-substrate interactions in order for RNH cleavages to 
occur.  The second reaction condition was pre-incubation of the enzyme with a mixture of 
substrate and inhibitor without the metal ions (denoted ESI), allowing us to probe for 
competitive inhibition with respect to the substrate.  The third condition evaluated was pre-
incubation of the enzyme with the substrate (denoted ES), resulting in binary complex formation 
of the enzyme-substrate prior to addition of the inhibitor and metal ions, allowing us to probe if 
the inhibitor can disrupt essential pre-formed enzyme-substrate contacts.  The fourth condition 
evaluated was without enzyme pre-incubation with the substrate or inhibitor (denoted E), such 
that the enzyme was added to a mixture of the substrate, inhibitor and metal ions.   
 Compound 25 was unable to inhibit RNH hydrolysis under conditions of pre-formed 
binary complexes (ES, IC50 > 25 M), where the greatest RT-RNH inhibition was seen during 
enzyme-inhibitor pre-incubation (EI) conditions with an IC50 of 0.4 M, as seen in Figure 26A.  
These results suggest that compound 25 is unable to displace the enzyme-substrate contacts but 
is able to prevent essential enzyme-substrate contacts from occurring when the inhibitor is pre-
bound to the enzyme.  It was further shown that the inhibitor is able to compete with the 
substrate for interaction with the enzyme, since experiments with enzyme, substrate and inhibitor 
pre-incubation (ESI) resulted in an increased IC50 of 20 M, indicating that the inhibitor is only 
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able to weakly competes with the substrates.  These results are further supported by the fact that 
compound 25 is unable to inhibit RNH catalysis in the absence of enzyme inhibitor pre-
incubation (E, IC50 > 25 M).  Similar results were seen with the p15-EC RT RNH domain with 
compound 25 (Figure 26B), having an approximate eighteen-fold increase in RNH IC50 of 
0.03M (EI) to 0.54 M (ES).  With p15-EC it is further shown that compound 25 competes 
with the substrate in order to inhibit RNH cleavages, since under ESI conditions the RNH 
inhibition has an approximate six-fold decrease in RNH inhibition (RNH IC50 0.17 M) and was 
unable to inhibit in the absence of pre-incubation (> 5 M RNH IC50). 
 
 
 
     
 
   
Figure 27.  Order of Addition Influence on RT-RNH Inhibition with Full Length RT using 
the Gel Based Dual Labeled RNH Assay.  A) RT-RNH inhibition of RNA 5'-end 
directed RNH cleavages (Duplex 2) and B) RT-RNH inhibition of DNA 3'-end 
directed RNH cleavages (Duplex 4).  Enzyme-inhibitor pre-incubation is denoted 
by EI, enzyme-substrate pre-incubation (binary complex) denoted by ES and 
enzyme-substrate-inhibitor pre-incubation denoted by ESI. 
 
 
 
The same order of addition studies were undertaken with the gel based dual labeled RNH assay 
with both the RNA 5'-end directed (duplex 2) and DNA 3'-end directed (duplex 4) cleavage 
A B 
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substrates.  The same trend was seen with the gel based assay as seen with the kinetic high-
throughput FRET RNH enzyme assay, with three of the most potent compounds 6, 15 and 25 
from subgroups A, B and C, respectively (Figure 27).  All three compounds were unable to 
inhibit the binary complex (ES),  while being able to completely inhibit DNA 3'-end and RNA 
5'-end directed cleavages under pre-incubation conditions of enzyme-inhibitor (EI) at 5M 
concentration.  Compound 6, the most potent compound with the gel based dual labeled RNH 
assay was the only inhibitor able to partly inhibit under ESI conditions with the gel based assay, 
suggesting the compound is able to compete with the substrate as seen in the high-throughput 
RNH FRET assay.  
 
 
2.4.8. Fluoren-9-ylidene Hydrazine Activity Against NNRTI Resistant Mutants 
 
 
Table 9.  Inhibition of NNRTI Resistant Mutants 
 
 
Compound 
Wild Type 
RT-RNH  
K103N/ L100V 
RT-RNH 
K103N/L100V 
RT- Pol 
 Y181C 
RT-RNH 
Y181C  
RT-Pol 
IC50 (M) IC50 (M) IC50 (M) IC50 (M) IC50 (M) 
      
15 0.34 0.39 0.42 0.88 1.0 
 
25 0.4 1.3 0.68 0.31 0.28 
 
  
Fluoren-9-ylidene hydrazine compounds 15 and 25 were evaluated as inhibitors of HIV-1 reverse 
transcriptase associated ribonuclease H and polymerase activities with clinically relevant NNRTI 
resistant mutants, K103N/ L100V (efavirenz resistant) and Y181C (nevirapine resistant) using 
the fixed time high-throughput FRET RNH enzyme assay with the high-throughput non-directed 
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cleavage substrate (HTS-1).  Both compounds were able to inhibit the RNH and polymerase 
activity of the NNRTI resistant mutants (Table 9) with similar IC50 values as wild type RT.  The 
ability of the compounds to retain similar inhibitory potency with the NNRTI resistant mutants, 
suggest that the fluoren-9-ylidene hydrazine compounds will be active against clinically relevant 
NNRTI resistant mutants that plague current patient therapy making this inhibitor class a 
promising class for future RNHI discovery.  These results further suggest that the fluoren-9-
ylidene hydrazine compounds would be unable to bind within or near the NNRTIBP, though this 
is only speculative and would require further studies to confirm this speculation.   
 
 
 
2.4.9   Fluoren-9-ylidene Hydrazine HIV-1 Antiviral Activity 
 
 
 
Table 10: HIV-1 Antiviral Activity of Select Fluoren-9-ylidene Hydrazine Compounds 
 
 
Subgroup Compound* HIV-1 EC50 (M) 
Toxicity* 
(Visual Assessment) 
Compounds* 
(No HIV-1 Antiviral Activity) 
 
A 
 
3 11 ± 0.5 ~ 10-25 2, 4, 6 
 
B 
 
15 10 ± 3 > 25 - 
 
C 
 
25 1.4 ± 0.6 > 25 26, 29, 31, 30, 33, 35, 37, 39, 41, 43, 44 
          * Compounds were evaluated up to 25 M 
  
  
 
HIV-1 antiviral dose response studies with P4R5 cells were carried out with 17 compounds from 
the fluoren-9-ylidene hydrazine library in which 3 of the compounds had antiviral activity, 
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compounds 3, 15 and 25, as seen in Table 10.  Compound 25, from subgroup C had the greatest 
antiviral activity with an EC50 of 1.4 ± 0.5 M and had no visual cytotoxic effects to 25 M.  
Eleven other compounds from subgroup C (26, 29, 31, 30, 33, 35, 37, 39, 41, 43, 44) were also 
evaluated for antiviral and cytotoxic activity up to 25 M, in which none of these compounds 
had antiviral activity or visual cytotoxic effects, except for compound 37 (displayed slight 
cytostatic activity was seen at 25 M).  The second most potent antiviral compound was from 
subgroup B, compound 15 with an EC50 of 10 ± 3 M and had no visual cytotoxic effects to 25 
M.  Compound 3 from subgroup A, displayed some antiviral activity but the actual EC50 value 
is a rough estimate, since slight cytostatic activity was seen from 10-25 M concentrations.  
Three other compounds from subgroup A (2, 4 and 6) were also evaluated for antiviral activity, 
in which they displayed no antiviral activity with HIV-1.  All three compounds, except 
compound 4, displayed no antiviral activity up to 25 M concentrations.  Compound 4 at the 
higher concentration of 25 M displayed some cell death, in which the cells displayed no 
cytotoxic effects at concentrations ≤ 15 M.   
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2.5 DISCUSSION 
 
 
 
 
Identification of the fluoren-9-ylidene hydrazines as a promising class of HIV-1 reverse 
transcriptase associated ribonuclease H inhibitors emerged from the screening of a library of 
hydrazone/hydrazine compounds.  Analysis of an expanded library of the fluoren-9-ylidene 
hydrazines demonstrated that the pharmacophore class provides highly active RNHIs.  Indeed, 
the expanded library of 118 compounds resulted in a hit rate of 55% (> 10 M IC50) as HIV-1 
RT RNHIs, in which the majority of the compounds were monofunctional as RNHI, since only 
21% of the compounds were able to inhibit RT-polymerase activity.   
 Active hits from the fluoren-9-ylidene hydrazine library were subgrouped into four 
functional groups, based on the functional group at the R1, including 2-(9H-fluoren-9-
ylidene)hydrazinecarboxamid(subgroup A), 2-(9H-fluoren-9-ylidene)hydrazinecarbothioamide 
(subgroup B), 1-(9H-fluoren-9-ylidene)-2-phenylhydrazine (subgroup C) and N’-(9H-fluoren-9-
ylidene) benzohydraside (Subgroup D).  The two most active RT RNHIs were compounds 15 
and 25 from subgroups B and C, having RT-RNH IC50 values of 0.34 ± 0.07 M and 0.4 ± 0.03 
M, respectably.  The other two subgroups, A and D were less potent as RT RNHIs.  Preliminary 
analysis of the structure activity relationship based on RT-RNH inhibition suggest that the R1 
phenyl substitution with and without a thioamide linker and an R2 sulfonamido-phenyl ring 
substituent significantly enhances RT-RNH inhibition, as seen with compounds 15 and 25.  
Furthermore, comparison of the fluoren-9-ylidene hydrazines with the 9H-(fluoren-9-ylidene)-2-
hydropranolcarboylhydrazine compounds, indicates the significance of the hydrazine 
functionality being planar.  The significance of these structural moieties seems to correlate with 
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antiviral activity, since both compounds 15 and 25 have antiviral activity, with EC50 values of 10 
± 3 M and 1.4 ± 0.6 M, respectively.  Compounds 15 and 25 also preferentially inhibit non-
directed and DNA 3'-end directed cleavages, suggesting they preferentially inhibit during active 
DNA polymerization. 
 The fluoren-9-ylidene hydrazine compounds were also able to directly interact and  
inhibit the RNH activity of the p15-EC RT RNH domain fragment, suggesting that the RNH 
inhibitory properties of these compounds is the result of direct interaction with the RNH domain 
of RT.  This observation suggest that the fluoren-9-ylidene hydrazine inhibitory properties are 
the result of directly binding with the RNH domain.  Kinetic studies with compound 25 further 
suggest direct binding with the RNH active, since compound the RT-RNH inhibition was 
competitive with respect to the RNA/DNA substrate, having a KI of 0.14M.  Additional order 
of addition studies, further supported competitive RNH inhibition with compounds 6, 15 and 25.  
Neither one of the compounds were able to inhibit the binary complex of the RNA/DNA 
substrate pre-bound to RT, while studies without enzyme-inhibitor pre-incubation had a 
complete loss or decrease in RT-RNH inhibition. 
 Fluoren-9-ylidene hydrazine compounds overall were much more potent RNH inhibitors 
of the p15-EC RT RNH domain fragment compared to the full length RT, in which compound 25 
had an approximate 13-fold difference in RNH inhibition.  None of the Fluoren-9-ylidene 
hydrazine compounds indicated any metal dependence with either  Mg+2 or Mn+2, along with no 
salt dependency, suggesting the difference in RNH inhibition with full length RT and the p15-EC 
RT  RNH domain fragment must be the result of different enzyme-substrate contacts.  It is 
expected that the smaller p15-EC RT RNH domain fragment would have a less extensive 
substrate contact network compared to full length RT and therefore the fluoren-9-ylidene 
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hydrazine should be greater inhibitors of the p15-EC RT RNH domain fragment activity versus 
full length RT.  In fact, this was the case where all of the fluoren-9-ylidene hydrazine compounds 
had a greater inhibition of the p15-EC RT RNH domain fragment.  Furthermore, order of 
addition studies with the p15-EC RT RNH domain fragment was still able to inhibit the binary 
complex with an eighteen-fold loss in RNH inhibitory potency.  These results indicating that the 
enhancement in RNH inhibition with the p15-EC RT RNH domain fragment is the result of 
having to disrupt less enzyme-substrate contacts compared to the more expansive contact 
network seen with full length RT.  We therefore propose that the fluoren-9-ylidene hydrazine 
compounds mechanism of RT-RNH inhibition is the result of competing with the substrate for 
the RNH active site.  
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CHAPTER 3: POTENTIAL BINDING SITE OF THE FLUOREN-9-YILDENE 
HYDRAZINE COMPOUNDS WITH THE p15-EC RT RNH DOMAIN FRAGMENT 
 
 
 
 
3.1 ABSTRACT 
  
 
 
 
To identify a potential binding site for the inhibitors, we performed solution NMR experiments 
of the p15-EC RT RNH domain fragment and molecular docking studies using the NMR results.  
First 1H-15N HSQC spectra of 15N-uniformely labeled p15-EC were recorded in the presence and 
absence of compound 25 with p15-EC, in which the inhibitor binds within the RNH active site.  
Second, bulk solvent affects due to DMSO and non-specific interaction were further ruled out by 
titrating only DMSO and a non-active compound 117 to p15-EC.  The NMR experiments clearly 
demonstrated that a region of p15-EC that includes the RNH active site residues were perturbed 
upon compound 25 interactions.  Molecular docking studies with compound 25 and the p15-EC, 
performed using these NMR results further supported a well-defined binding pocket within the 
RNH active site.  The hydrazine functionality of compound 25 forms hydrogen bonds with 
catalytic essential metal coordinating residues E52 (RT: 478) and D72 (RT: 498).  Along with an 
R2 sulfonamido-phenyl ring substituent stacks with an essential residue for RNH catalysis, H125 
(RT: 539) by making edge on-π interactions.  
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3.2 INTRODUCTION 
 
 
 
 
Solution NMR 1H-15N HSQC experiments for the p15-EC RT RNH domain fragment were 
carried out to identify a potential binding site for the fluoren-9-ylidene hydrazine compounds.  
The most active RNHI, compound 25 was titrated to the protein sample to characterize residues 
whose chemical shifts were perturbed upon interaction.  An inactive compound, 117 from the 
library was also evaluated  in order to rule out any non-specific binding interaction.  We chose 
NMR experiments rather than X-ray crystallography since previous X-ray crystallography 
studies of full-length RT complex with RNHIs did not exhibit the inhibitor in a reasonable 
position to reduce RNH activity (43, 90) 
 Biochemical experiments showed that compound 25 exhibited significant RNH inhibition 
on the p15-EC RT RNH domain fragment, therefore the NMR experiments were carried out with 
the smaller 16.7 kDa p15-EC RT RNH domain fragment versus the 117 kDa full length RT.  The 
p15-EC enzyme is suitable to compare RNH inhibition and binding site information.  As 
previously shown, backbone NMR signals of the p15-EC have already been assigned and have 
been significantly perturbed upon inhibitor interaction with the enzyme (35).  Previous studies 
with the fluoren-9-ylidene hydrazine library and the p15-EC discussed in chapter 2, have 
identified these inhibitors to be more potent as RNH inhibitors with the p15-EC versus full 
length RT.  Additionally, previous studies also indicated that compound 25 is a competitive 
inhibitor for RT RNH activity with respect to the substrate, suggesting this inhibitor binds within 
the RNH active site.  Based on the observations it was of a greater advantage to use solution 
NMR studies with the p15-EC versus other biophysical techniques in order to deduce a potential 
binding site. 
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3.3 MATERIALS AND METHODS 
 
 
 
 
3.3.1   Reagents 
 
 
The M9 media consisted of 42 mM dibasic sodium phosphate, 22 mM monobasic potassium 
phosphate and 8.5 mM sodium chloride (7.4 pH), with added supplements of 100 mM 
magnesium sulfate , 10 mM calcium chloride,  1 mg/ml thiamine, 1 mg/ml d-biotin, 1.3 g/ml  
kanamycin, 0.2% glucose  and 0.1%  ammonium chloride.  All regents used for protein 
expression and NMR experiments were of the highest grade available.  HiTrap Q HP Sepharose 
ion exchange and a HiTrap SP columns and a superdex 75 26/60 size exclusion column were  
obtained from  GE Healthcare, Piscataway, NJ, USA. 5-mm shigemi tubes were obtained from 
Shigemi Inc., Allison Park, PA, USA.  
 
 
 
 
3.3.2  Isotropic Labeling of  the p15-EC RT RNH Domain Fragment 
 
 
The p15-EC RT RNH domain fragment was isotropically labeled for NMR experiments by 
growing pCSR231-transformed bacterial cell cultures in a modified M9 minimal media with 
15NH4Cl as the only nitrogen source.  Purification was carried out with a HiTrap Q HP Sepharose 
ion exchange and a HiTrap SP column, with 25 mM sodium phosphate buffer (7.0 pH), 0.02% 
sodium azide and 1 mM dithiothreitol (DTT) used to equilibrate the column, while a linear 
gradient 1 M NaCl solution was used to elude the protein.  A Superdex75 26/60 size exclusion 
column with a 25 mM sodium phosphate buffer (7.0 pH), 0.02% sodium azide, 100 mM NaCl 
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and 1 mM DTT was used to further purify the RNase H fragment.  Purity of the protein was 
assessed with 20% SDS-PAGE gel electrophoresis and all samples were stored at 70˚C until use.  
 
 
 
3.3.3   Solution NMR 1H-15N HSQC 
 
 
All spectra were recorded on a Bruker AVANCE600 spectrometers equipped with a 5-mm-
triple-resonance-z-gradient cyogenic probe at 25°C.  The p15-EC protein was dissolved in a 40 
mM sodium phosphate buffer (6.8 pH), with 95%H2O/5%D2O, at 60 M protein concentration 
and placed into a 5-mm shigemi tube with a total volume of ~350l.  A stock solution of 
compound 25 was prepared at 50 mM in 100% DMSO, while compound 117 was prepared at 10 
mM in 100% DMSO.  First, the p15-EC spectra were recorded in the absence and presence of 
0.3 and 0.9% DMSO to assess the effects of DMSO on the protein.  Second, the p15-EC spectra 
were recorded at different concentrations of compound 25: 0, 60 and 90 M (corresponding to 
1:0, 1:1 and 1:1.5 ratio with DMSO concentrations of 0, 0.2 and 0.3% DMSO).  Third, the p15-
EC spectra recorded in the presence of compound 117 at 0 and 90 M (corresponding to 1:0, and 
1:1.5 ratios with DMSO concentrations of 0 and 0.9%), in order to rule out any none specific 
binding with the fluoren-9-yldiene hydrazine compounds.  Each spectra obtained in the absence 
and presence of DMSO or inhibitor were carried out under the same conditions over an eight 
hour period per spectrum.  Previosuly assigned Chemical shifts peaks of the backbone 1H-15N 
signals (11) were used to assess changes in the resonance peak in the current experiments.  
Degree of chemical shift perturbations upon inhibitor titration was assess by taking the square 
root of the sum of squares of the 1H and 15N chemical shift peak differences.  The effect of 
inhibitor interaction was also investigated by determining the degree of peak intensity changes 
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upon inhibition titration by also taking the square root of the sum of squares of the 1H and 15N 
peak intensity differences. Chemical shift and peak intensity perturbations were considered to 
significant above the cutoff line of 1.24 Hz  for chemical shift data and 0.05  for peak intensity 
data.  The cutoff lines were determined by taking the standard deviation of the chemical shift 
perturbation values or the change in peak intensity values for all the residues.  NMR spectra of 
p15-EC were also recorded in the presence of DMSO and the chemical shift changes induced by 
the either 0.3 or 0.9% DMSO were subtracted from their corresponding inhibitor spectra.  All 
NMR data was processed and analyzed using the NMRDraw and NMRView software packages 
(18, 50). 
 
 
 
3.3.4   Molecular Docking with Schrödinger Suite Software 
 
The Schrodinger Suite XP glide docking program (Schrödinger, LLC., New York, NY) was used 
for molecular docking of compound 25 to the p15-EC RT RNH domain fragment.  The p15-EC 
RT RNH domain fragment was previously created (35) by inserting the extended E. coli loop 
(TQWIH NWKKR GWKTA DKKPV KNV) to the PDB file 2I5J.  Molecular docking was 
performed in the following strategy.  First, based on the NMR results, the binding region was 
selected and centered on residue G18 with a 12Å area.  Second, the top 15 lowest energy 
confirmations of compound 25 at a pH 8.0 ± 0.5 using the ConfGen application were selected for 
docking within the defined docking area.  Lastly, all 15 confirmations of compound 25 were 
docked within the defined binding region centering on residue G18, in which the inhibitors were 
allowed to be flexible while the protein was maintained at its minimized conformation.  The top 
5 docked structure with the greatest glide docking score and favorable protein contacts within an 
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4Å area were selected and analyzed.  The glide docking score (gscore) is based on the energy 
contributions from van der Waals interactions (vdW), coulombic interactions (Coul), lipophilic-
contacts with phobic-attractive interactions (Lipo), hydrogen bonding interactions (Hbond), and 
the polar interactions within the binding site (Site), in which the gscore is based on equation 
 gscore = a * vdW + b * Coul + Lipo + Hbond + Reward + Site.  The docked models were also 
assessed based on their Emodel score, this score takes into the account the gscore, CvdW (non-
bonded internal energy between the ligand and receptor, CvdW = Coul + VdW) and the 
estimated conformational energy of the ligand.  All protein and ligand preparations and 
hydrogenation was carried out at a pH range of 8.0 ± 0.5, in order to correlate with biochemical 
data.  
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3.4 RESULTS 
 
 
 
 
     3.4.1 Influence of DMSO on the 1H-15N HSQC Spectrum of p15-EC  
 
 
 
 
 
 
Figure 28.  Amid Backbone Chemical Shift Perturbations of the p15-EC RT RNH Domain  
Fragment Induced by DMSO at  A) 0.3% and B) 0.9% DMSO.  
 
 
 
 1H-15N HSQC solution NMR studies of  p15-EC were recorded in the presence of DMSO 
at 0.3 and 0.9% (both spectra are found within the appendix B: Supplementary Figures 1 and 2.  
These experiments were carried out, to identify any effects of solvent DMSO that is required to 
 86 
 
dissolve the fluoren-9-ylidene hydrazine compounds in aqueous solution.  As seen in Figure 28, 
most of the residue signals chemical shifts did not change and are primarily unaffected by the 
small amounts of DMSO.  However, some residues (Y15, G18, A19, S63, Q82) did experience 
slight chemical shift changes at 0.3% DMSO.  A few residues (T46, W92 and V136) exhibited 
more chemical shift perturbations at the higher concentration of DMSO at 0.9%.  Inconsistency 
in the slight chemical shift changes in the presence of 0.3% and 0.9% DMSO may have arisen 
due to initial solution inhomogeneity of the DMSO concentration during mixing of it into the 
protein solution. However, as shown below, these inconsistencies were insignificant in the 
inhibitor titration experiments since the chemical shift differences were so small. 
 
 
3.4.2 Influence of Compound 25 on the 1H -15N HSQC Spectrum of p15-EC 
 
 
In order to deduce a potential binding site for the  fluoren-9-ylidene RNHIs, 1H-15N HSQC 
solution NMR titration studies were carried out with compound 25 and p15-EC, since  previous 
experiments (from chapter 2) indicated competitive RNH inhibition with the substrate and 
therefore suggesting direct interaction with the RNH active site.  Inhibitor p15-EC spectra were 
collected at compound 25 concentrations of 0, 60 and 90 M (corresponding to 1:0, 1:1 and 1:1.5 
ratio with DMSO concentrations of 0, 0.2 and 0.3% DMSO).  Titration studies beyond a ratio of 
1:1.5 were not performed due to the limitation of the solubility of compound 25 in aqueous 
solution.  
  A few residue chemical shift perturbations were observed beyond the cutoff of 1.24 Hz 
for compound 25, as seen in Figure 29A.  The DMSO solvent affects were removed from residue 
chemical perturbations of compound 25, such that the DMSO residue chemical shift 
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perturbations were subtracted from the residue chemical shift perturbations of compound 25 with 
DMSO.  As seen in Figure 29C, residues that experienced chemical shift perturbations were G18 
(RT: 444) with 6.1 Hz, T46 (RT: 472) with 1.4 Hz, Q82 (extended loop residue) with 3.5 Hz, 
H85 (extended loop residue) with 1.4 Hz, W123 (RT: 535) with 3.3 Hz, and V124 (RT: 536) 
with 1.5 Hz.  G18 (RT: 444).  Residue G18 (RT: 444) resides at the base of the RNH active site, 
neighboring catalytic active site residues D17 (RT:443) and has been shown to be significantly 
affected upon metal binding with p15-EC by solution NMR titration studies previously done in 
our laboratory (35).  Furthermore residue T46 (RT: 472), is also neighboring essential residues 
responsible for interacting with the RNA/DNA substrate, residues T47 (RT: 473), N48 (RT: 474) 
and Q49 (RT: 475) (70).  Residues Q82 and H85 are located in the extended E. coli helix-loop 
that is important for restoring activity to the p15-EC RT RNH domain fragment by interacting 
with the substrate.  Alignment of the RNH domain fragment with full-length RT structure 
indicates the extended E. coli helix-loop may mimic inter-subunit interactions between the p51 
and p66 subunits of RT with the RNH domain (35).  Resides W123 (RT: 535) and V124 (RT: 
536) are highly conserved hydrophobic residues that neighbor the active site near catalytic 
residue D72 (RT: 498), in which residue V124 (RT: 536) has further been implemented to 
experience chemical shift changes upon metal interactions of the p15-EC RT RNH domain 
fragment during solution NMR titration studies (35).  Active site residue E52 (RT: 478), 
essential for protein-metal contacts has the greatest change in peak intensity of 1.6 (Figure 30C). 
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Figure 29.  Amide Backbone Chemical Shift Perturbations of p15-EC Induced by  
Compound 25.  A) Compound 25 in the presence of 0.3% DMSO, B) 0.3% 
DMSO and C) the subtraction of B from A. 
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Figure 30.  Amide Backbone Peak Intensity Changes of p15-EC Induced by Compound 25.  
A) Compound 25 in the presence of 0.3% DMSO, B) 0.3% DMSO and C) the 
subtraction of B from A. 
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3.4.3   Influence of Compound 117 on the 1H -15N HSQC Spectrum of p15-EC 
 
 
 
 
 
Figure 31.  Amid Backbone Chemical Shift Perturbations of p15-EC Induced by   
Compound 117.  A) Compound 117 in the presence of 0.9% DMSO, and 
B) 0.3% DMSO  and C) the subtraction of B from A. 
 
 
 
 1H-15N HSQC solution NMR studies were carried out with compound 117 in order to rule 
out any amide backbone chemical shift perturbations seen upon binding of compound 25 with 
p15-EC was not the result of to non-specific interaction.  For this purpose, the 1H-15N HSQC 
spectrum was recorded in the absence and presence of compound 117 (does not inhibit p15-EC).  
A higher DMSO percentage was required with compound 117, therefore a 0.9% DMSO 
chemical shift differences spectrum was used as a comparison and removed from compound 
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12.5).  The non-bonded interaction energy between the ligand and receptor had a score of -47.7, 
resulting in a favorable Emodel score of -63.7.  As seen in the Figure 32, compound 25 sets 
within a well-defined pocket up against the active site.  The inhibitor is mainly surrounded by 
hydrophobic (highlighted green) and polar (highlighted cyan) residues, while the hydrazine 
functionality hydrogen bonds with catalytic active site residues E52 (RT: 478) and D72 (RT: 
498), that are essential for metal coordination (also observed during docking studies with 
compound 15) (Figure 33).  The hydrogen bonding distance with residues E52 (RT: 478) and 
D72 (RT: 498) are ~2.4 Å with the greatest energy contributions due to van der waals interaction 
with scores of -3.7 and -3.2, while having a hydrogen bonding score of -0.024 and -0.032.  The 
inhibitor is further seen to interact with residues that experienced chemical shift changes during 
the NMR experiments, G18 (RT: 444), W123 (RT: 535) and V124 (RT: 536).  The R2 
sulfonamido-phenyl ring substituent (Figure 33) is located at a position to form edge-on-π 
interaction with residue H127 (RT: 539) that is critical for RNH catalysis.  The sulfonamido-
phenyl ring was 1.9Å from H127 (RT:539), in which the greatest interaction contribution was 
due to van der waals interactions with a score of -2.1, while having a slightly favorable 
coulombic interaction score of -0.74.  The dock structure also shows that though the fluoren-9-
ylidene hydrazine core is tucked into the binding pocket and is away from the solvent; the 
furthest ends of the R1 and R2 extensions are partially solvent exposed, as indicated in Figure 33 
by the yellow highlights.  One of the ortho-iodine of the R2 sulfonamido-phenyl ring substituent 
is also seen to be oriented towards a polar residue, Q49 (RT: 475) with a 2.8 Å distance, this 
residue is significant for enzyme-substrate contacts.  The proximity of the inhibitor with residue 
Q49 (RT: 475) suggests that an ionic interaction between the negative iodine and amine of the 
glutamine residue may stabilizes the solvent exposed phenyl ring.  An additional contact is seen 
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with residue N48 (RT: 474), which is also a significant enzyme-substrate contact residue.  The 
inhibitor is ~2.5 Å from residue N48 (RT: 474) with a favorable van der waals interaction score 
of -4.6 and coulombic interaction score of -3.6.  
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3.5 DISCUSSION 
 
 
 
 
A potential binding site for compound 25 with the p15-EC RT RNH domain fragment was 
defined based on amide backbone chemical shift perturbation from 1H-15N HSQC solution NMR 
studies, where peak intensity changes were not used to define the pocket since the peak intensity 
changes above the cutoff line of 0.05 were not localized to a specific region of p15-EC. Amide 
backbone chemical shift perturbations were seen with residues G18 (RT: 444), T46 (RT: 472), 
W123 (RT: 535), and V124 (RT: 536), along with residues Q82 and H85, that are located within 
the extended E. coli helix-loop added in order to restore activity to the isolated enzyme (54).   
Chemical shift perturbation of the extended E. coli helix-loop residues, Q82 and H85 were 
excluded as being the result of direct inhibitor binding, since the chemical shift perturbations by 
compound 25 were small and were observed during the DMSO titrations.  The remaining four 
residues G18 (RT: 444), T46 (RT: 472), W123 (RT: 535) and V124 (RT: 536) were located in or 
around the RNH active site, in which residue G18 (RT: 444) experienced the greatest chemical 
shift perturbations of 6.1 Hz.  Residue G18 (RT: 444) resides within the RNH active site 
neighboring catalytic actives residue D17 (RT: 443) and near other active site residues E52 (RT: 
478) and D72 (RT: 498).  The amide backbone chemical shift of residue G18 (RT: 444) has been 
shown to be significantly affected upon metal binding with the p15-EC RT RNH domain 
fragment (35).  Signal intensity of one of the active site residues E52 (RT: 478) was significantly 
enhanced by compound 25, suggesting that the RNHI makes specific contact with this residue 
upon binding to the p15-EC RT RNH domain fragment.  Residues W123 (RT: 535) and V124 
(RT: 536) are highly conserved hydrophobic residues that neighbor the active site near catalytic 
residue D72 (RT: 498), in which residue V124 (RT: 536) has been shown to experience amide 
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backbone chemical shift perturbations upon metal binding with the p15-EC RT RNH domain 
fragment (35).  Residue T46 (RT: 472) neighbors residues essential for enzyme-substrate 
interaction, including residues T47 (RT: 473),  N48 (RT: 474) and Q49 (RT: 475) (26).  The 1H-
15N-HSQC NMR results suggest that compound 25 binds within the RNH active site, in which 
the binding pocket revolves around residue G18 (RT: 444) and involves residues T46 (RT: 472), 
W123 (RT: 535) and V124 (RT: 536), while interacting with active site residue E52 (RT: 478). 
 Compound 25 was able to be docked within a well-defined pocking within the RNH 
active site.  Furthermore, residues deduced during the NMR studies, including G18 (RT: 444), 
E52 (RT: 478), W123 (RT: 535) and V124 (RT: 536), created the binding site.  Indeed, the 
upper-back-side wall of the binding pocket consisted of residues W123 (RT: 535) and V124 (RT: 
536), while the other backside of the wall contained residues T47 (RT: 473) and Q49 (RT: 475) 
that neighbor residue T46 (RT: 472) and have been shown to be significant for enzyme-substrate 
contacts (75).  The third neighboring residues of T46 (RT: 472), residue N48 (RT: 474) is also a 
significant enzyme-substrate contact residue and resides at the base of the binding pocket near 
residue G18 (RT: 444).  In addition, residue G18 (RT: 444) resides at the base of the active site 
binding pocket and contributes largely to the binding pocket floor, along with active site residues 
D17 (RT: 443) and D137 (RT: 549).  The essential hydrazine functionality of compound 25 
makes hydrogen bonds with metal coordinating active site residues E52 (RT: 478) and D72 (RT: 
478).  The hydrogen bonding interactions correlate with the biochemical and biophysical data, 
such that the hydrazine planarity and functionality is essential for RT-RNH inhibition, while 
residue E52 (RT: 478) has significant residue peak intensity changes indicating direct interaction 
with the inhibitor.  The R2 sulfonamido-phenyl ring substituent making edge-on-pi contact with 
H127 (RT: 539), also correlates with the biochemical structure activity relationship data, such 
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that the R2 sulfonamido-phenyl ring substituent has been shown to enhance RT-RNH inhibitioniv.  
These results suggest that the inhibitors interaction with H127 (RT: 539) prevents RNH catalysis 
from transpiring, since mutation of H127 (RT: 539) completely abrogates RNH activity.  The 
molecular docking observations based on the NMR studies, propose that the fluoren-9-ylidene 
hydrazine RNHIs mechanism of inhibition involves binding within the RNH active site and 
preventing access of RNH essential catalytic residues to the RNA/DNA substrate.  This 
conclusion is supported by the fact that the fluoren-9-ylidene RNHIs are competitive inhibitors 
with the substrate, are unable to inhibit the binary complex when enzyme-substrate contacts are 
pre-formed and the NMR studies identities residue-inhibitor interactions with neighboring active 
site residues essential for substrate binding. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
iv H127 peak was not distinqueshed within the p15-EC RT RNH domain Fragment specturms. 
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CHAPTER 4: SUMMARY AND CONCLUSIONS 
 
 
 
 
4.1   Major Findings and Conclusions 
 
 
 
 
4.1.1   Chapter 2: Identification and Characterization of the Fluoren-9-yildene Hydrazine  
Pharmacophore 
 
 
The fluoren-9-ylidene hydrazine pharmacophore was identified as a highly active inhibitor of 
HIV-1 reverse transcriptase associated ribonuclease H activity, having a 55% hit rate, in which 
79% of the compounds were monofunctional as RNHIs (< 10 M IC50).  The most active RT-
RNHIs were compounds 15 (IC50 of 0.34 ± 0.07 M) and 25 (IC50 of 0.4 ± 0.03 M), in which 
compound 25 had the greatest antiviral activity (EC50 of 1.4 ± 0.6 M).  Compound 25 was 
further able to inhibit the p15-EC RT RNH domain fragment with a ten-fold increase in potency 
(IC50 of 0.032 ± 0.004 .  Preliminary structure-activity relationship studies with full length 
RT further indicate that the RNH inhibitory activity of the fluoren-9-ylidene hydrazine 
compounds is dependent on the planarity of the group, while also indicating that an R1 phenyl 
and R2 sulfonamido-phenyl ring substituents significantly enhances RT-RNH inhibition.  
Competitive inhibition with respect to the RNA/DNA substrate with both full length RT and the 
p15-EC RT RNH domain fragment, along with the ability to retain inhibitory activity against 
NNRTI resistant mutants suggest that compound 25 interaction with the RNH active site and 
compete with the RNA/DNA substrate. 
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4.1.2   Chapter 3: Potential Binding Site of the Fluoren-9-yildene Hydrazine Compounds  
with the p15-EC RT RNH Domain Fragment 
 
 
1H-15N HSQC solution NMR residue amide backbone chemical shift and intensity perturbations 
indicate that compound 25 binds within the RNH active site of the p15-EC RT RNH domain 
fragment, in which the binding pocket involves residues G18 (RT: 444), T46 (RT: 472), W123 
(RT: 535) and V124 (RT: 536) and has direct interaction with active site residue E52 (RT: 478).  
Biased molecular docking studies with compound 25 and the p15-EC RT RNH domain fragment 
indicate that the inhibitor is able to be docked within the RNH active site, while interacting with 
specific residues identified from the NMR studies.  In addition the hydrazine functionality 
directly hydrogen bonds with active site metal coordinating resides E52 (RT: 478) and D72 (RT: 
498).  The R2 sulfanamido-phenyl substituent makes edge-on-π interactions with essential RNH 
hydrolysis residue H127 (RT: 539), correlating with the previous observations that the R2 
sulfanamido-phenyl group subsitituent has an enhancement on RT-RNH inhibition.  The binding 
pocket is further formed by significant residues for enzyme-substrate contacts, T47 (RT: 473), 
N48 (RT: 474) and Q49 (RT: 475) (75).  This proposed binding site based on NMR and 
molecular modeling studies imply that the mechanism of RNH inhibition by the fluoren-9-
ylidene hydrazine class of compounds involves binding within a well-defined pocket with the 
RNH active site.  Therefore, preventing significant enzyme-substrate contacts from transpiring 
and possibly perturbing residues essential for RNH hydrolysis, and subsequently preventing 
RNH hydrolysis from transpiring.  
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4.2 Significance and Future Studies 
 
 
 
The current studies with the fluoren-9-ylidene hydrazine library identifies a new class of highly 
active HIV-1 reverse transcriptase associated ribonuclease H inhibitors with a pharmacophore 
that has not previously been described as an HIV-1 RNHI.  Biochemical and structural 
biophysical studies propose a novel mechanism of HIV-1 RT-RNH inhibition, in which 
inhibition is the result of the inhibitor binding with RNH active site residues essential for both 
substrate and metal ion interactions that is independent of active site metal chelation.  The 
binding mode of the inhibitor prevents access of essential catalytic RNH residues to the 
RNA/DNA substrate and subsequently inhibits RNH catalysis from being carried out.  These 
studies suggest that compounds with the fluoren-9-ylidene hydrazine functionality as HIV-1 
antivirals have a potential for less off-target interaction that could be determinate to the host.  
Furthermore, the lead compounds within this study have antiviral activity against HIV-1 and are 
able to inhibit clinically relevant NNRTI resistant mutants during in vitro studies, therefore 
identifying the fluoren-9-ylidene hydrazine class of RNHIs as a promising lead for further 
studies in HIV-1 RT RNHI discovery that is independent of RNH active site metal chelation. 
 Future studies that could be continued from this current study, would be to develop 
fluoren-9-ylidene hydrazine derivatives with enhanced RT-RNH inhibition based on the 
currently proposed binding mode.  For instance, based on the molecular docking studies with 
compound 25, the ortho iodine of the R2 sulfonamido-phenyl ring substituent has a potential to 
make ionic interactions with residue  K128 (RT: 540).  Addition of a second ortho iodine 
substituent may enhance the inhibitor-enzyme contacts and subsequently enhance RT-RNH 
inhibition.   
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Supplementary Table 1:  Screening Results of the (9H-fluoren-9-ylidene)hydrazine Library 
 
 
 
 
 
           IC50 (M)  
Compound R1 R2 R3 
HIV-1  
RT-RNH 
HIV-1  
RT-Pol 
RT-RNH 
Domain 
Fragment 
A.     2-(9H-fluoren-9-ylidene)hydrazinecarboxamid     
1 
 
 
 
 
-H 1.1 ± 0.2 5.6 ± 0.6 0.36 ± 0.13 
2 
 
 
 
 
-H 1.8 ± 0.4 8.1 ± 0.9 0.24 ± 0.02 
3 
 
 
  
-H 2.4 ± 0.1 6 ± 1 1.3 ± 0.1 
4 
 
-H 3 ± 0.6 9.6 ± 0.5 1.2 ± 0.07 
N
HN
R1
R3 R3
R2
R2
NH2
O
S
O
O
N
NH2
O
S N
O
O
N
N
NH2
O
S
H
N
O
O
H3C
NH2
O
S
H
N
O
O
APPENDIX A 
 
102 
 
 
 
5 
 
 
  
-H 3.5 ± 0.3 7.4 ± 1.3 0.5 ± 0.09 
       
6 
 
 
 
  
6 ± 0.1 >25 0.23 ± 0.04 
7 
 
 
 
  
6.4 ± 0.6 >25 1.9 ± 0.07 
8 
 
 
 
 
-H 9 ± 1 >25 1.9 ± 0.5 
9 
 
 
  
-H 13 ± 0.1 21 ± 1 3.5 ± 0.04 
10 
 
 
 
 
-H >25 >25 15 ± 0.13 
11 
 
 
 
 
-H >25 >25 >25 
NH2
O
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CH3
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12 
 
 
 
 
 
-H >25 >25 >25 
13 
 
 
 
 
-H >25 >25 >25 
14 
 
 
 
 
-H >25 >25 >25 
B.    2-(9H-fluoren-9-ylidene)hydrazinecarbothioamide     
15 
 
 
 
 
-H 0.34 ± 0.07 0.62 ± 0.06 0.43 ± 0.04 
16 
 
 
 
-H -H 0.76 ± 0.1 2.3 ± 0.1 0.16 ± 0.02 
17 
 
 
 
-H -H 1.3 ± 0.4 22 ± 2 0.34 ± 0.03 
18 
 
 
 
-H -H 1.6 ± 0.3 >25 0.05 ± 0.02 
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19 
 
 
 
-H -H 5.6 ± 0.6 >25 0.6 ± 0.04 
20 
 
 
 
-H -H 11 ± 0.5 >25 2.5 ± 0.3 
21 
 
 
 
-H -H 12 ± 0.9 >25 3.8 ± 0.2 
22 
 
 
 
-H -H >25 >25 15 ± 1.3 
23 
 
 
 
-H -H >25 >25 >25 
24 
 
 
 
-H -H >25 >25 >25 
        
N
H
S
O
CH3
N
H
S
N
H
S
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C.   1-(9H-fluoren-9-ylidene)-2-phenylhydrazine     
25 
 
 
  
-H 0.4 ± 0.03 1.5 ± 0.1 0.032 ± 0.004 
26 
 
 
  
-H 0.58 ± 0.05 5 ± 0.5 0.082 ± 0.02 
27 
 
 
 
-H -H 0.68 ± 0.1 1.3 ± 0.2 0.070 ± 0.003 
28 
 
 
 
-H -H 0.79 ± 0.1 3.4 ± 0.7 0.036 ± 0.005 
29 
 
 
  
-H 1.4 ± 0.3 2.3 ± 0.2 0.072 ± 0.006 
30 
 
 
 
 
-H 1.6 ± 0.2 3.6 ± 0.8 0.49 ± 0.08 
31 
 
 
  
-H 1.7 ± 0.1 8.6 ± 0.2 0.35 ± 0.02 
S
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32 
 
 
 
-H -H 1.9 ± 0.7 6.2 ± 0.3 0.2 ± 0.0 
       
33 
 
 
-H 2 ± 0.1 12 ± 1 0.23 ± 0.02 
       
34 
 
 
 
-H -H 2 ± 0.3 14 ± 0.4 0.29 ± 0.04 
35 
 
 
 
 
-H 2.1 ± 0.2 11 ± 0.3 0.67 ± 0.09 
36 
 
 
 
-H -H 2.2 ± 0.4 2.6 ± 0.3 0.087 ± 0.008 
37 
 
 
  
-H 2.4 ± 0.5 0.7 ± 0.3 0.28 ± 0.03 
38 
 
-H -H 2.4 ± 0.2 12 ± 1.4 0.23 ± 0.03 
S N O
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39 
 
 
  
-H 2.7 ± 0.01 4.6 ± 0.9 0.43 ± 0.1 
40 
 
 
 
-H -H 2.83 ± 0.5 14 ± 0.4 >25 
41 
 
 
 
-H 3 ± 0.2 >25 0.16 ± 0.02 
42 
 
 
 
-H -H 3.7 ± 0.5 >25 >25 
43 
 
 
  
-H 3.7 ± 0.4 5 ± 0.4 0.12 ± 0.02 
44 
 
 
  
-H 4.4 ± 0.3 8.2 ± 0.7 1.4 ± 0.2 
45 
 
 
 
-H -H 4.4 ± 0.6 >25 0.27 ± 0.008 
46 -H -H 4.7 ± 0.2 >25 0.33 ± 0.04 
S O
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47 
 
 
 
-H -H 4.8 ± 1.6 >25 0.24 ± 0.03 
48 
 
 
 
-H -H 6.1 ± 0.2 >25 0.26 ± 0.07 
49 
 
 
 
-H -H 6.2 ± 0.4 >25 0.56 ± 0.08 
50 
 
 
 
-H -H 7.7 ± 0.9 >25 0.4 ± 0.05 
51 
 
 
 
-H -H 10 ± 2 >25 0.28 ± 0.08 
52 -H -H 11 ± 0.7 >25 0.54 ± 0.04 
53 
 
 
 
-H -H 11 ± 2 >25 0.064 ± 0.005 
       
H3C
CH3
CH3
N
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Cl
F
F
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Cl
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54 
 
 
 
-H -H >25 >25 >25 
55 
 
 
 
-H -H >25 >25 3.6 ± 0.3 
56 
 
 
 
-H -H >25 >25 4.2 ± 0.1 
57 
 
 
 
-H -H >25 >25 0.09 ± 0.06 
 
D.    N’-(9H-fluoren-9-ylidene)benzohydraside    
 
58 
 
 
-H -H 1.3 ± 0.2 2.3 ± 0.2 0.018 ± 0.001 
59 
 
 
 
-H -H 1.5 ± 0.2 3.6 ± 0.7 0.26 ± 0.03 
N+
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60 
 
 
 
 
-H -H 2.1 ± 0.2 >25 0.26 ± 0.06 
61 -H -H 2.3 ± 0.2 14 ± 0.4 0.37 ± 0.06 
62 
 
 
 
-H -H 2.6 ± 0.02 >25 0.52 ± 0.03 
63 
 
 
 
-H -H 2.6 ± 0.8 1.0 ± 0.2 0.063 ± 0.02 
64 
 
 
 
-H -H 2.8 ± 0.3 13 ± 0.4 0.36 ± 0.09 
65 
 
 
 
-H -H 3.1 ± 0.4 >25 0.41 ± 0.06 
66 
 
 
 
-H -H 3.1 ± 0.2 >25 0.45 ± 0.05 
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67 
 
 
 
-H -H 3.5 ± 0.8 >25 0.77 ± 0.03 
68 
 
 
 
-H -H 4.3 ± 0.8 >25 0.84 ± 0.1 
69 
 
 
 
-H -H 4.5 ± 0.4 >25 2.2 ± 0.2 
70 
 
 
-H -H 4.9 ± 0.5 21 ± 0.2 2.2 ± 0.2 
71 
 
 
 
-H -H 5.8 ± 0.2 >25 3.9 ± 0.1 
72 
 
 
 
-H -H 6.5 ± 0.3 >25 2.5 ± 0.3 
73 
 
 
 
-H -H 8 ± 0.02 17 ± 3 4.4 ± 0.5 
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74 
 
 
 
-H -H 9 ± 1 >25 4 ± 0.3 
75  
 
 
-H -H 10 ± 0.3 >25 5.4 ± 0.3 
76 
 
 
 
-H -H 12 ± 2 >25 2.4 ± 0.04 
77 
 
 
 
-H -H 14 ± 0.6 >25 7.2 ± 0.6 
78 
 
 
 
-H -H 15 ± 2 >25 3.4 ± 0.2 
79 
 
 
 
-H -H 15 ± 1 >25 7.5 ± 0.3 
80 
 
-H -H 15 ± 2 >25 3.5 ± 0.9 
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81 
 
 
-H -H 16 ± 0.5 >25 8.2 ± 0.2 
82 
 
 
 
-H -H 17 ± 0.6 >25 5.6 ± 2 
83 
 
 
 
-H -H 18 ± 0.2 >25 14 ± 0.8 
84 
 
 
 
-H -H 18 ± 2 >25 6.8 ± 0.8 
85 
 
 
 
-H -H 19 ± 2 >25 14 ± 0.4 
86 
 
 
 
-H -H 22 ± 2 >25 11 ± 0.5 
87 
 
-H -H 22 ± 4 >25 4.8 ± 0.06 
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88 
 
 
 
-H -H >25 >25 >25 
89 
 
 
 
-H -H >25 >25 >25 
90 
 
 
 
-H -H >25 >25 4.5 ± 0.9 
91 
 
 
 
-H -H >25 >25 >25 
92 
 
 
 
-H -H >25 >25 >25 
       
93 
 
 
 
-H -H >25 >25 2.2 ± 0.2 
       
94   
 
-H -H >25 >25 >25 
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95   
 
-H -H >25 >25 0.23 ± 0.05 
       
E.   Other    
96 
 
 
 
 
-H 0.5 ± 0.06 1.7 ± 0.1 0.5 ± 0.03 
97 
 
 
 
-H -H 1.7 ± 0.2 >25 0.3 ± 0.02 
98 
 
 
 
-H -H 1.8 ± 0.1 9.4 ± 1.6 0.33 ± 0.06 
99 
 
 
 
-H -H 2.2 ± 0.2 13 ± 3 0.11 ± 0.01 
100 
 
 
 
-H -H 2.5 ± 0.3 11 ± 0.5 0.31 ± 0.04 
101 
 
-H -H 3.3 ± 0.2 >25 0.33 ± 0.07 
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102 
 
 
 
-H -H 3.3 ± 0.5 >25 1.4 ± 0.09 
103 
 
 
 
-H -H 3.7 ± 0.3 13 ± 1 3.8 ± 0.1 
104 
 
 
 
-H -H 6 ± 0.4 >25 0.24 ± 0.01 
105 
 
-H -H 11 ± 2 >25 2.3 ± 0.2 
106 
 
 
 
 
-H -H 14 ± 2 >25 >25 
107 
 
 
 
-H -H 14 ± 3 >25 2.6 ± 0.6 
108 
 
 
 
-H -H 21 ± 4 >25 0.71 ± 0.2 
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109  
 
 
-H -H >25 >25 1.7 ± 0.2 
110  
 
 
-H -H >25 >25 1.7 ± 0.2 
111 
 
 
 
-H -H >25 >25 4.3 ± 0.5 
112 
 
 
 
-H -H >25 >25 5.3 ± 0.02 
113 
 
 
 
-H -H >25 >25 >25 
114 
 
 
 
-H -H >25 >25 >25 
       
115 
 
-H -H >25 >25 >25 
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116 
 
 
 
 
-H >25 >25 >25 
117 
 
 
 
 
-H >25 5.7 ± 1.5 >25 
118 
 
 
 
-H -H >25 >25 >25 
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Supplementary Figure 1:  Overlay of 1H-15N HSQC of p15-EC RT RNH Domain Fragment with Compound 117 and DMSO Spectra 
 
Black = p15-EC with no drug or DMSO (02.16 sample) 
Red = 0.3% DMSO 
Blue = 0.9% DMSO 
Green = 90M Compound 117 and 0.9% DMSO 
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Supplementary Figure 2:  Overlay of 1H-15N HSQC p15-EC RT RNH Domain Fragment Compound 25 and DMSO Spectra  
 
 Black = p15-EC with no drug or DMSO (02.16 sample) 
Red = p15-EC with no drug or DMSO (03.17 sample) 
Green = 90M Compound 25 with 0.3% DMSO 
Blue = 0.3% DMSO 
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ABBREVIATIONS
 
 
 
AIDS - acquired immunodeficiency syndrome 
AMV - alfalfa mosaic virus (or lucerene mosaic virus) 
 
BBNH - N-(4-tert-Butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone 
BTDBA - 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid 
 
CC50 -half-maximal cytotoxicity concentration 
CPHM - 4-chlorophenylhydrazone of mesoxalic acid 
 
DDDP - DNA dependent DNA polymerase 
DHBNH - dihydroxy benzoyl naphthyl hydrazone 
DKA - diketo acids 
dsDNA - double stranded DNA 
dsRNA - double stranded RNA 
 
 
E - enzyme is not pre-incubated 
EC50 - half-maximal effective concentration 
EI - enzyme pre-incubated with an inhibitor 
ES - enzyme pre-incubated with the RNA/DNA substrate 
ESI - enzyme pre-incubated with RNA/DNA substrate and an inhibitor 
 
HIV - human immunodeficiency virus 
HSQC - heteronuclear single quantum coherence 
HTS - high-throughput substrate (refer to Table 2, subsection 2.3.4) 
 
IC50 - half-maximal inhibitor concentration 
IN - integrase 
 
Kcat - catalytic rate of an enzyme 
Kd - dissociation constant 
Km - Michaelis-Menton constant 
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ABBREVIATIONS (continued) 
 
 
MLV - murine leukemia virus 
 
NCME - 5-nitro-furan-2-carboxylic carbamoylmethyl ester 
NEM - N-ethylmaleimide 
NMR - nuclear magnetic resonance 
NNRTI - non-nucleoside reverse transcriptase inhibitor 
NNRTIBP - non-nucleoside reverse transcriptase inhibitor binding pocket 
 
PBS - primer binding site 
PDB - protein data bank 
pol - polymerase  
PR - protease 
p15-EC - RT RNH domain fragment 
p51 - 51 kDa subunit of HIV-1 reverse transcriptase 
p66 - 66 kDa subunit of HIV-1 reverse transcriptase 
 
RDDP - RNA dependent DNA polymerase 
RFU - relative fluorescence units 
RDS-1643 - 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester 
RNH - ribonuclease H domain 
RNHI - ribonuclease H inhibitor 
RT - reverse transcriptase 
 
9-AN - photoactive analogue of nevirapine 
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